EP2197916A1 - Dose fixe d'injection unique d'ocrelizumab (2h7) - Google Patents

Dose fixe d'injection unique d'ocrelizumab (2h7)

Info

Publication number
EP2197916A1
EP2197916A1 EP08804245A EP08804245A EP2197916A1 EP 2197916 A1 EP2197916 A1 EP 2197916A1 EP 08804245 A EP08804245 A EP 08804245A EP 08804245 A EP08804245 A EP 08804245A EP 2197916 A1 EP2197916 A1 EP 2197916A1
Authority
EP
European Patent Office
Prior art keywords
antibody
chain
seq
full length
humanized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08804245A
Other languages
German (de)
English (en)
Inventor
David Robert Close
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of EP2197916A1 publication Critical patent/EP2197916A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention relates to the treatment of autoimmune diseases, including rheumatoid arthritis, by administration of a CD20 antibody, using a treatment regimen that includes a single intravenous infusion of the full effective dosage at the outset of treatment.
  • Lymphocytes are one of several populations of white blood cells; they specifically recognize and respond to foreign antigen.
  • the three major classes of lymphocytes are B lymphocytes (B cells), T lymphocytes (T cells) and natural killer (NK) cells.
  • B lymphocytes are the cells responsible for antibody production and provide humoral immunity.
  • B cells mature within the bone marrow and leave the marrow expressing an antigen-binding antibody on their cell surface.
  • a naive B cell first encounters the antigen for which its membrane-bound antibody is specific, the cell begins to divide rapidly and its progeny differentiate into memory B cells and effector cells called "plasma cells".
  • Memory B cells have a longer life span and continue to express membrane-bound antibody with the same specificity as the original parent cell. Plasma cells do not produce membrane-bound antibody but instead produce secreted form of the antibody. Secreted antibodies are the major effector molecules of humoral immunity.
  • the CD20 antigen also called human B-lymphocyte-restricted differentiation antigen, Bp35
  • Bp35 human B-lymphocyte-restricted differentiation antigen
  • CD20 is thought to regulate an early step(s) in the activation process for cell cycle initiation and differentiation (Tedder et al, supra) and possibly functions as a calcium ion channel (Tedder et al. J. Cell. Biochem. 14D:195 (1990)).
  • CD20 is also a useful target antigen for treating autoimmune diseases.
  • the rituximab (RITUXAN®, Mabthera® in Europe) antibody which is a genetically engineered chimeric murine/human monoclonal antibody directed against human CD20 antigen (commercially available from Genentech, Inc., South San Francisco, California, U.S.) is used for the treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B cell non-Hodgkin's lymphoma.
  • Rituximab is the antibody referred to as "C2B8" in US Patent No. 5,736,137 issued April 7, 1998 (Anderson et al.) and in US Pat No. 5,776,456.
  • Rituximab has also been studied in a variety of non-malignant autoimmune disorders, in which B cells and autoantibodies appear to play a role in disease pathophysiology. Edwards et al, Biochem Soc. Trans. 30:824-828 (2002). Rituximab has been reported to potentially relieve signs and symptoms of, for example, rheumatoid arthritis (RA) (Leandro et al., Ann. Rheum. Dis. 61:883-888 (2002); Edwards et al, Arthritis Rheum., 46 (Suppl. 9): S46 (2002); Stahl et al, Ann. Rheum. Dis., 62 (Suppl.
  • RA rheumatoid arthritis
  • rituximab The reported safety profile of rituximab in a small number of patients with neurologic disorders, including autoimmune neuropathy (Pestronk et al, supra), opsoclonus-myoclonus syndrome (Pranzatelli et al, supra), and RRMS (Cross et al, supra), was similar to that reported in oncology or RA.
  • Patents and patent publications concerning CD20 antibodies, CD20-binding molecules, and self-antigen vaccines include US Patent Nos. 5,776,456, 5,736,137, 5,843,439, 6,399,061, and 6,682,734, as well as US 2002/0197255, US 2003/0021781, US 2003/0082172, US 2003/0095963, US 2003/0147885, US 2005/0186205, and WO 1994/11026 (Anderson et al); US Patent No.
  • rituximab was found to be a well-tolerated, effective remission induction agent for severe ANCA-associated vasculitis, when used in a dose of 375 mg/m 2 x 4 along with oral prednisone 1 mg/kg/day, which was reduced by week 4 to 40 mg/day, and to complete discontinuation over the following 16 weeks.
  • Four patients were re-treated with rituximab alone for recurring/rising ANCA titers.
  • no additional immunosuppressive agents seem to be necessary for remission induction and maintenance of sustained remission (6 months or longer).
  • Trubion Pharmaceuticals Inc. has recently evaluated the safety and efficacy of an anti-CD20 antibody fragment-type molecule designated TRU-015 in a Phase lib randomized, double-blind, placebo-controlled, multicenter clinical trial conducted with 276 patients with rheumatoid arthritis who were also receiving methotrexate as background therapy. The patients were randomized evenly into five groups that received either placebo, 200 mg, 400 mg, 800 mg or 1600 mg of TRU-015, administered as a single intravenous infusion. TRU-015 was reported to be generally well tolerated.
  • the present invention satisfies this need by providing a new protocol for the administration of CD20 antibodies for the treatment of autoimmune diseases.
  • the invention concerns a method of depleting B cells in a human patient having an autoimmune disease comprising administering to the patient a complete therapeutically effective amount of a CD20 antagonist as a single intravenous (i.v.) infusion. Therefore, the invention relates to a use of a CD20 antagonist in the manufacture of a medicament for treatment of an autoimmune disease, wherein the medicament is for administration to a human patient in a single therapeutically effective intravenous (i.v.) infusion of said antagonist.
  • said administration is followed by a second i.v. infusion of a complete therapeutically effective amount of the CD20 antagonist in 4 to 6 months after the first administration.
  • the second administration usually takes place when the patient treated responds to the first treatment but shows signs of relapse.
  • said administration of said second i.v. infusion is for administration to a patient who responds to but relapses following the first administration.
  • the therapeutically effective amounts for administration at the first and second i.v. infusions are essentially the same.
  • the CD20 antagonist is a CD20 monoclonal antibody.
  • the CD20 monoclonal antibody is chimeric, humanized or human. More preferably, the CD20 antibody is a humanized 2H7 antibody.
  • the autoimmune disease is selected from the group consisting of rheumatoid arthritis, systemic lupus erythematosus (SLE), lupus nephritis, ulcerative colitis, Crohn's disease, Sjogren's syndrome, neuromyelitis optica (NMO), ANCA associated- vasculitis, Wegener's disease, inflammatory bowel disease, idiopathic thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), autoimmune thrombocytopenia, multiple sclerosis, psoriasis, IgA nephropathy, IgM polyneuropathies, myasthenia gravis, diabetes mellitus, Reynaud's syndrome, and glomerulonephritis.
  • SLE systemic lupus erythematosus
  • NMO neuromyelitis optica
  • ANCA associated- vasculitis Wegener's disease
  • the autoimmune disease is rheumatoid arthritis. In an even more preferred embodiment, the autoimmune disease is active rheumatoid arthritis. In a most preferred embodiment, the active rheumatoid arthritis is moderate to severe rheumatoid arthritis.
  • the patient treated showed inadequate response to previously administered methotrexate, TNF antagonists, and/or other anti-CD20 antagonists, including CD20 antibodies other than the antibody administered in accordance with the present invention.
  • the therapeutically effective amount in the use according to the invention is typically between 10 mg and 2000 mg, preferably between about 400 mg and 1500 mg. In separate embodiments, the therapeutically effective amount is 400mg, lOOOmg, and 1500mg.
  • the autoimmune disease is rheumatoid arthritis and the CD20 antibody is a humanized 2H7 antibody.
  • the humanized CD20 antibody (1) is selected from the group consisting of 2H7 Variants A, B and I, comprising a full length L chain of SEQ ID NO: 6 and a full length heavy chain of SEQ ID NO: 7, 8 and 15, respectively, or a fragment thereof; or (2) is 2H7 Variant A comprising a full length L chain of SEQ ID NO: 6 and a full length H chain of SEQ ID NO: 7, or a fragment thereof; or (3) an antibody that binds to essentially the same epitope as 2H7 Variant A comprising a full length L chain of SEQ ID NO: 6 and a full length H chain of SEQ ID NO: 7, or a fragment thereof; or (4) is selected from the group consisting of 2H7 Variants C, D, F, G, and H comprising a full length L chain of SEQ ID NO: 9 and a full length H chain of SEQ ID NO: 10, 11, 12, 13, and 14 respectively, or a fragment thereof; of (5) is 2H7 Variant B comprising a
  • the CD20 antibody is the human antibody HUMAX- CD20TM
  • the CD20 antibody is for administration in conjunction with a drug selected from the group consisting of nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, glucocorticosteroids, cyclophosphamide, adalimumab, leflunomide, infliximab, etanercept, ofatumumab, tocilizumab, AME-133, Immu-106, and COX-2 inhibitors.
  • NSAIDs nonsteroidal anti-inflammatory drugs
  • the use is for administration comprising a second therapeutic agent, which can, for example, be an immunosuppressive agent.
  • a second therapeutic agent which can, for example, be an immunosuppressive agent.
  • the use comprises methotrexate.
  • methotrexate is for administration dose of 10 to 25 mg/week.
  • the use comprises administration of one to six DMARDS prior to administration of the CD20 antibody. In yet another embodiment, the use comprises no steroid treatment prior to the administration of the CD20 antibody.
  • the invention concerns a use of a CD20 antibody in the manufacture of a medicament for treatment of active rheumatoid arthritis (RA), wherein the medicament is for administration to a human patient in a single therapeutically effective intravenous (i.v.) infusion of said antibody in a dosage of 400 mg to 1500 mg. More preferably, the dose is selected from the group consisting of 400 mg, 1000 mg or 1500 mg.
  • RA active rheumatoid arthritis
  • the antibody can be a chimeric, humanized or human monoclonal antibody, and may, for example, be any of the CD20 antibodies listed above.
  • the invention relates to a use of 2H7 Variant A comprising a full length L chain of SEQ ID NO: 6 and a full length H chain of SEQ ID NO: 7, or a fragment thereof, in the manufacture of a medicament for treatment of active rheumatoid arthritis (RA), wherein the medicament is for administration to a human patient in a single therapeutically effective intravenous (i.v.) infusion of said antibody in a dosage of 400 mg.
  • RA active rheumatoid arthritis
  • the invention relates to a use of 2H7 Variant A comprising a full length L chain of SEQ ID NO: 6 and a full length H chain of SEQ ID NO: 7, or a fragment thereof, in the manufacture of a medicament for treatment of active rheumatoid arthritis (RA), wherein the medicament is for administration to a human patient in a single therapeutically effective intravenous (i.v.) infusion of said antibody in a dosage of 1000 mg.
  • RA active rheumatoid arthritis
  • the invention relates to a use of 2H7 Variant A comprising a full length L chain of SEQ ID NO: 6 and a full length H chain of SEQ ID NO: 7, or a fragment thereof, in the manufacture of a medicament for treatment of active rheumatoid arthritis (RA), wherein the medicament is for administration to a human patient in a single therapeutically effective intravenous (i.v.) infusion of said antibody in a dosage of 1500 mg.
  • RA active rheumatoid arthritis
  • the CD20 antibody is for administration which is not followed by a second administration of a CD20 antibody for at least 1 month, or at least 2 months, or at least 3 months, or at least 4 months.
  • the invention concerns a method for the treatment of active rheumatoid arthritis (RA) in a human patient comprising administering to the patient 400 mg of 2H7 Variant A comprising a full length L chain of SEQ ID NO: 6 and a full length H chain of SEQ ID NO: 7, or a fragment thereof.
  • RA active rheumatoid arthritis
  • the invention concerns a method for the treatment of active rheumatoid arthritis (RA) in a human patient comprising administering to the patient 1000 mg of CD20 antibody 2H7 Variant A comprising a full length L chain of SEQ ID NO: 6 and a full length H chain of SEQ ID NO: 7, or a fragment thereof.
  • RA active rheumatoid arthritis
  • the first administration is not followed by a second administration of a CD20 antibody for at least 1 month, or at least 2 months, or at least 3 months, or at least 4 months.
  • the initial infusion rate may be within the normal standard range of infusion rates, such as, for example, between 50 mg/hr and 100 mg/hr.
  • the infusion rate does not need to be the same during the entire time of administration, rather can be escalated, e.g. as described in Example 1.
  • the invention concerns an article of manufacture comprising: (a) a container comprising a CD20 antagonist; and (b) a package insert with instructions for treating an autoimmune disease in a human subject, wherein the instructions indicate that the subject is administered the complete therapeutically effective amount of the CD20 antagonist as single intravenous infusion.
  • the CD20 antagonist is a chimeric, humanized or human CD20 monoclonal antibody.
  • the autoimmune disease is rheumatoid arthritis.
  • the CD20 antagonist is CD20 antibody 2H7 Variant A comprising a full length L chain of SEQ ID NO: 6 and a full length H chain of SEQ ID NO: 7, or a fragment thereof.
  • the instructions indicate a complete therapeutically effective amount between 400 mg and 1500 mg.
  • the article of manufacture comprises: (a) a container comprising a CD20 antibody; and (b) a package insert with instructions for treating rheumatoid arthritis in a human subject, wherein the instructions indicate that the subject is administered a complete therapeutically effective amount between 400 mg and 1500 mg of a CD20 antibody as single intravenous infusion. More preferably, in the article of manufacture according to the invention the
  • CD20 antibody is humanized 2H7 Variant A comprising a full length L chain of SEQ ID NO: 6 and a full length H chain of SEQ ID NO: 7, or a fragment thereof.
  • said humanized 2H7 Variant A is formulated at 20 mg/ml antibody in 10 mM histidine sulfate, 60 mg/ml sucrose, 0.2 mg/ml polysorbate 20, and Sterile Water for Injection, at pH 5.8.
  • the invention concerns a pharmaceutical formulation comprising a complete effective amount of a CD20 antibody in a form suitable for onetime intravenous administration.
  • the pharmaceutical formulation according to the invention comprises the CD20 antibody which is humanized 2H7 Variant A comprising a full length L chain of SEQ ID NO: 6 and a full length H chain of SEQ ID NO: 7, or a fragment thereof.
  • the pharmaceutical formulation comprises an effective amount between 400 mg and 1500 mg. Even more preferably, said amount is selected from the group of 400 mg, 1000 mg or 1500 mg.
  • said humanized 2H7 Variant A is formulated at 20 mg/ml antibody in 10 mM histidine sulfate, 60 mg/ml sucrose, 0.2 mg/ml polysorbate 20, and Sterile Water for Injection, at pH 5.8.
  • B cell is a lymphocyte that matures within the bone marrow, and includes a naive B cell, memory B cell, or effector B cell (plasma cells), in all stages of development.
  • the B cell herein is a normal or non-malignant B cell.
  • B cell depletion refers to a reduction in B cell levels in an animal or human after drug or antibody treatment, as compared to the level before treatment. B cell levels are measurable using well known assays such as by getting a complete blood count, by FACS analysis staining for known B cell markers, and other methods well known in the art. In one embodiment, the depletion of CD20 expressing B cells is at least 25%. In a patient receiving a B cell depleting drug, B cells are generally depleted for the duration of time when the drug is circulating in the patient's body and the time for recovery of B cells.
  • B-cell surface marker or "B-cell surface antigen” or “B cell antigen” herein is an antigen expressed on the surface of a B cell that can be targeted with an antagonist that binds thereto.
  • Exemplary B-cell surface markers include the CDlO, CD 19, CD20, CD21, CD22, CD23, CD24, CD37, CD40, CD53, CD72, CD73, CD74, CDw75, CDw76, CD77, CDw78, CD79a, CD79b, CD80, CD81, CD82, CD83, CDw84, CD85 and CD86 leukocyte surface markers (for descriptions, see The Leukocyte Antigen Facts Book, 2 nd Edition. 1997, ed. Barclay et al.
  • B-cell surface markers include RP 105, FcRH2, B-cell CR2, CCR6, P2X5, HLA- DOB, CXCR5, FCER2, BR3, Btig, NAG14, SLGC16270, FcRHl, IRTA2, ATWD578, FcRH3, IRTAl, FcRH6, BCMA, and 239287.
  • the B-cell surface marker of particular interest is preferentially expressed on B cells compared to other non-B-cell tissues of a mammal and may be expressed on both precursor B cells and mature B cells.
  • the preferred B-cell surface markers herein are CD20 and CD22.
  • CD20 antigen is an about 35-kDa, non-glycosylated phosphoprotein found on the surface of greater than 90% of B cells from peripheral blood or lymphoid organs. CD20 is present on both normal B cells as well as malignant B cells, but is not expressed on stem cells. Other names for CD20 in the literature include "B-lymphocyte-restricted antigen” and "Bp35". The CD20 antigen is described in Clark et al, Proc. Natl. Acad. Sci. (USA) 82:1766 (1985), for example.
  • a "CD20 antagonist” is a molecule that, upon binding to CD20 on B cells, destroys or depletes B cells in a mammal and/or interferes with one or more B-cell functions, e.g. by reducing or preventing a humoral response elicited by the B cell.
  • the CD20 antagonist preferably is able to deplete B cells ⁇ i.e. reduce circulating B-cell levels) in a mammal, such as a human subject, treated therewith. Such depletion may be achieved via various mechanisms such as ADCC and/or CDC, inhibition of B-cell proliferation and/or induction of B-cell death ⁇ e.g. via apoptosis).
  • Antagonists included within the scope of the present invention include antibodies, other CD20 targeted (binding) proteins, synthetic or native-sequence peptides, immunoadhesins, and small- molecule antagonists that bind to CD20, optionally conjugated with or fused to another molecule.
  • the preferred antagonist is, consists of, consists essentially of or comprises an antibody.
  • an “antibody antagonist” herein is an antibody that, upon binding to a B-cell surface marker on B cells, destroys or depletes B cells in a mammal and/or interferes with one or more B-cell functions, e.g., by reducing or preventing a humoral response elicited by the B cell.
  • the antibody antagonist preferably is able to deplete B cells (i.e., reduce circulating B-cell levels) in a mammal treated therewith. Such depletion may be achieved via various mechanisms such as ADCC and/or CDC, inhibition of B-cell proliferation and/or induction of B-cell death (e.g., via apoptosis).
  • a “CD20 antibody antagonist” or an “antagonist CD20 antibody” is an antibody that, upon binding to CD20 on B cells, destroys or depletes B cells in a mammal, such as a human subject, and/or interferes with one or more B-cell functions, e.g., by reducing or preventing a humoral response elicited by the B cell.
  • CD20 antagonist antibodies include rituximab (Genentech), TRU-015 (Trubion, Wyeth), ofatumumab (HuMax-CD20; Genmab); AME- 133 (Eli Lilly), Immu-106 (Immunomedics), all referenced in the background section.
  • the term "inadequate response to a CD20 antagonist” refers to an inadequate response to previous or current treatment with a CD20 antagonist because of toxicity and/or inadequate efficacy.
  • the inadequate response can be assessed by a clinician skilled in treating the disease in question.
  • a mammal, such as human, who experiences "toxicity" from previous or current treatment with the CD20 antagonist experiences one or more negative side-effects associated therewith such as cardiac, pulmonary, renal side- effects, especially severe side effects, such as acute respiratory distress syndrome, myocardial infarction, ventricular fibrillation, cardiogenic shock, hypoxia, pulmonary infiltrates, acute renal failure, mucocutaneous reactions, or infections, such as viral infections.
  • autoimmune disease and "autoimmune disorder” are used interchangeably, and refer to a disease or disorder arising from and directed against an individual's own tissues or a co-segregate or manifestation thereof or resulting condition therefrom.
  • Autoimmune disease can be an organ-specific disease (i.e., the immune response is specifically directed against an organ system such as the endocrine system, the hematopoietic system, the skin, the cardiopulmonary system, the gastrointestinal and liver systems, the renal system, the thyroid, the ears, the neuromuscular system, the central nervous system, etc.) or a systemic disease which can affect multiple organ systems (for example, systemic lupus erythematosus (SLE), rheumatoid arthritis, polymyositis, etc.).
  • organ system such as the endocrine system, the hematopoietic system, the skin, the cardiopulmonary system, the gastrointestinal and liver systems, the renal system, the thyroid, the ears, the neuromuscular system, the central nervous system, etc.
  • a systemic disease which can affect multiple organ systems (for example, systemic lupus erythematosus (SLE), rheumatoid arthritis, polymyositis, etc.).
  • autoimmune diseases or disorders include, but are not limited to autoimmune rheumatologic disorders, such as arthritis (rheumatoid arthritis such as acute arthritis, chronic rheumatoid arthritis, gouty arthritis, acute gouty arthritis, chronic inflammatory arthritis, degenerative arthritis, infectious arthritis, Lyme arthritis, proliferative arthritis, psoriatic arthritis, vertebral arthritis, and juvenile-onset rheumatoid arthritis, osteoarthritis, arthritis chronica progrediente, arthritis deformans, polyarthritis chronica primaria, reactive arthritis, and ankylosing spondylitis), inflammatory hyperproliferative skin diseases, psoriasis such as plaque psoriasis, gutatte psoriasis, pustular psoriasis, and psoriasis of the nails, atopy including atopic diseases such as hay fever and Job's syndrome, dermatitis including contact dermatitis, chronic contact dermatitis,
  • rheumatoid arthritis or "RA” is used herein in the broadest sense and refers to a recognized disease state which may be diagnosed according to the 2000 revised American Rheumatoid Association criteria for the classification of rheumatoid arthritis, or any similar criteria.
  • Physiological indicators of RA include, symmetric joint swelling which is characteristic though not invariable in rheumatoid arthritis. Fusiform swelling of the proximal interphalangeal (PIP) joints of the hands as well as metacarpophalangeal (MCP), wrists, elbows, knees, ankles and metatarsophalangeal (MTP) joints are commonly affected and swelling is easily detected.
  • PIP proximal interphalangeal
  • MCP metacarpophalangeal
  • MTP metatarsophalangeal
  • Pain on passive motion is the most sensitive test for joint inflammation, and inflammation and structural deformity often limits the range of motion for the affected joint. Typical visible changes include ulnar deviation of the fingers at the MCP joints, hyperextension or hyperflexion of the MCP and PIP joints, flexion contractures of the elbows, and subluxation of the carpal bones and toes.
  • the subject with rheumatoid arthritis may be resistant to DMARDs, in that the DMARDs are not effective or fully effective in treating symptoms.
  • Rheumatoid arthritis can be described as mild, moderate, or severe. Mild RA is characterized by the involvement of at least 3 joints (simultaneously) with no extra- articular disease.
  • the rheumatoid factor is typically negative and there are no erosions on the radiographs.
  • Moderate disease includes active inflammation of 6-20 joints and usually involves radiograph changes and a positive RF-there are typically no extra-articular manifestations.
  • Moderate disease suggests the need for an NSAID and DMARD together, as opposed to simply NSAID therapy.
  • Severe RA is characterized by the involvement of more than 20 joints, includes positive RF (usually high titer) and extra-articular disease, and typically additionally causes other systemic effects including hypoalbuminemia and anemia of chronic disease. There is rapidly decreasing functional capacity in the severe form of RA.
  • rheumatoid arthritis includes all forms and stages of RA, including, without limitation, active rheumatoid arthritis, early and late RA based on how long the patient has had RA, and moderate to severe rheumatoid arthritis.
  • Rheumatoid factor is an immunoglobulin directed against the Fc portion of another immunoglobulin commonly used as a blood test for the diagnosis of rheumatoid arthritis. It can self-aggregate into a lattice-like form within joint cavities to provide a surface onto which inflammatory cells can adhere and act. Rheumatoid arthritis patients with a high titer of RF (approximately 80% of patients) have more aggressive disease, with a worse long-term outcome and increased mortality over those who are RF negative.
  • a patient with “active rheumatoid arthritis” means a patient with active and not latent symptoms of rheumatoid arthritis.
  • active rheumatoid arthritis is defined by the presence of at least 4 swollen joints.
  • Subjects with “early active rheumatoid arthritis” are those subjects with active rheumatoid arthritis diagnosed for at least 8 weeks but no longer than four years, according to the revised 1987 ACR criteria for the classification of RA.
  • Treating” or “treatment” or “alleviation” refers to therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder.
  • a subject is successfully “treated” for an autoimmune disease if, after receiving a therapeutic amount of a CD20 antagonist, such as a CD20 binding antibody of the invention according to the methods of the present invention, the subject shows observable and/or measurable reduction in or absence of one or more signs and symptoms of the particular autoimmune disease.
  • the target disease is rheumatoid arthritis
  • those in need of treatment include those already with the disease as well as those in which the development of the disease, including various characteristics of the disease, such as joint damage or the progress of joint damage, is to be prevented.
  • the subject may have been diagnosed as having rheumatoid arthritis or may be predisposed or susceptible to rheumatoid arthritis, or may have mild or moderate rheumatoid arthritis, which is likely to progress in the absence of treatment.
  • Treatment is successful if the disease and/or various characteristics or symptoms of the disease, is/are alleviated or healed, or progression of the disease is halted or slowed down as compared to prior to administration.
  • Successful treatment further includes complete or partial prevention of the development of the disease.
  • slowing down or reducing the disease or symptoms of the disease or the progression of symptoms of the disease is the same as arrest, decrease, or reversal in the symptoms.
  • Symptoms of rheumatoid arthritis include any of the symptoms listed in the 2000 revised American Rheumatoid Association criteria for the classification of rheumatoid arthritis, such as, for example, joint swelling, joint damage, bone deformity, bone erosion, pain, inflammation, and systemic effects associated with more advance forms of rheumatoid arthritis, including hypoalbuminemia and anemia of chronic disease.
  • an “effective amount” refers to an amount of a CD20 antibody or another CD20 antagonist that is effective for treating (including prevention) of rheumatoid arthritis.
  • an “effective amount” the target disease and/or various characteristics or symptoms of the disease, is/are alleviated or healed, or progression of the disease is halted or slowed down as compared to prior to administration.
  • Successful treatment further includes complete or partial prevention of the development of the disease. For purposes herein, slowing down or reducing the disease or symptoms of the disease or the progression of symptoms of the disease is the same as arrest, decrease, or reversal in the symptoms.
  • Symptoms of rheumatoid arthritis include any of the symptoms listed in the 2000 revised American Rheumatoid Association criteria for the classification of rheumatoid arthritis, such as, for example, joint swelling, joint damage, bone deformity, bone erosion, pain, inflammation, and systemic effects associated with more advance forms of rheumatoid arthritis, including hypoalbuminemia and anemia of chronic disease.
  • the phrase "complete therapeutically effective amount" administered as a "single intravenous (i.v.) infusion” is used herein to mean that the total amount of a CD20 antagonist, such as a CD20 antibody, that is effective in the therapeutic treatment of a target disease, such as rheumatoid arthritis, is administered as a single i.v. infusion, instead of administration of two or more partial dosages (smaller than the therapeutically effective amount) consecutively, in separate infusions such as several days or weeks apart.
  • the "CD20” antigen is a non-glycosylated, transmembrane phosphoprotein with a molecular weight of approximately 35 kD that is found on the surface of greater than 90% of B cells from peripheral blood or lymphoid organs. CD20 is expressed during early pre-B cell development and remains until plasma cell differentiation; it is not found on human stem cells, lymphoid progenitor cells or normal plasma cells. CD20 is present on both normal B cells as well as malignant B cells. Other names for CD20 in the literature include "B-lymphocyte-restricted differentiation antigen" and "Bp35". The CD20 antigen is described in, for example, Clark and Ledbetter, Adv. Can. Res. 52:81- 149 (1989) and Valentine et al. J. Biol. Chem. 264(19): 11282-11287 (1989).
  • antibody is used in the broadest sense and specifically covers monoclonal antibodies (including full length monoclonal antibodies), multispecific antibodies ⁇ e.g., bispecific antibodies), single chain antibodies and antibody fragments so long as they exhibit the desired biological activity or function.
  • the biological activity of the CD20 binding antibodies of the invention will include binding of the antibody to human CD20, more preferably binding to human and other primate CD20 (including cynomolgus monkey, rhesus monkey, chimpanzees, baboons).
  • the antibodies will bind CD20 with a Kd value of no higher than 1 x 10 "8 , preferably a IQ value no higher than about 1 x 10 "9 , and be able to kill or deplete B cells in vivo, preferably by at least 20% when compared to the appropriate negative control which is not treated with such an antibody.
  • B cell depletion can be a result of one or more of ADCC, CDC, apoptosis, or other mechanism.
  • specific effector functions or mechanisms may be desired over others and certain variants of the humanized 2H7 or certain human CD20 binding antibodies are preferred to achieve those biological functions, such as ADCC.
  • Antibody fragments comprise a portion of a full length antibody, generally the antigen binding or variable region thereof .
  • antibody fragments include Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.
  • Fv is the minimum antibody fragment which contains a complete antigen-recognition and -binding site. This fragment consists of a dimer of one heavy- and one light-chain variable region domain in tight, non-covalent association. From the folding of these two domains emanate six hypervariable loops (3 loops each from the H and L chain) that contribute the amino acid residues for antigen binding and confer antigen binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.
  • monoclonal antibody refers to an antibody from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical and/or bind the same epitope(s), except for possible variants that may arise during production of the monoclonal antibody, such variants generally being present in minor amounts.
  • Such monoclonal antibody typically includes an antibody comprising a polypeptide sequence that binds a target, wherein the target-binding polypeptide sequence was obtained by a process that includes the selection of a single target binding polypeptide sequence from a plurality of polypeptide sequences.
  • the selection process can be the selection of a unique clone from a plurality of clones, such as a pool of hybridoma clones, phage clones or recombinant DNA clones.
  • the selected target binding sequence can be further altered, for example, to improve affinity for the target, to humanize the target binding sequence, to improve its production in cell culture, to reduce its immunogenicity in vivo, to create a multispecific antibody, etc., and that an antibody comprising the altered target binding sequence is also a monoclonal antibody of this invention.
  • each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen.
  • the monoclonal antibody preparations are advantageous in that they are typically uncontaminated by other immunoglobulins.
  • the modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method.
  • the monoclonal antibodies to be used in accordance with the present invention may be made by a variety of techniques, including, for example, the hybridoma method (e.g., Kohler et al, Nature, 256:495 (1975); Harlow et al, Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling et al, in: Monoclonal Antibodies and T-CeIl Hybridomas 563-681, (Elsevier, N.Y., 1981)), recombinant DNA methods (see, e.g., U.S. Patent No.
  • phage display technologies see, e.g., Clackson et al, Nature, 352:624-628 (1991); Marks et al, J. MoI Biol, 222:581-597 (1991); Sidhu et al, J. MoI Biol. 338(2):299-310 (2004); Lee et al, J.Mol.Biol 340(5): 1073-1093 (2004); Fellouse, Proc. Nat. Acad. Sci. USA 101(34): 12467-12472 (2004); and Lee et al J. Immunol.
  • Methods 284(1-2): 119-132 (2004) and technologies for producing human or human-like antibodies in animals that have parts or all of the human immunoglobulin loci or genes encoding human immunoglobulin sequences (see, e.g., WO 1998/24893; WO 1996/34096; WO 1996/33735; WO 1991/10741; Jakobovits et al, Proc. Natl. Acad. Sci. USA, 90:2551 (1993); Jakobovits et al, Nature, 362:255-258 (1993); Bruggemann et al, Year in Immuno., 7:33 (1993); U.S. Patent Nos.
  • “Functional fragments” of the CD20 binding antibodies of the invention are those fragments that retain binding to CD20 with substantially the same affinity as the intact full length molecule from which they are derived and show biological activity including depleting B cells as measured by in vitro or in vivo assays such as those described herein.
  • variable refers to the fact that certain segments of the variable domains differ extensively in sequence among antibodies.
  • the V domain mediates antigen binding and define specificity of a particular antibody for its particular antigen.
  • variability is not evenly distributed across the 110-amino acid span of the variable domains.
  • the V regions consist of relatively invariant stretches called framework regions (FRs) of 15-30 amino acids separated by shorter regions of extreme variability called “hypervariable regions” that are each 9-12 amino acids long.
  • FRs framework regions
  • hypervariable regions that are each 9-12 amino acids long.
  • the variable domains of native heavy and light chains each comprise four FRs, largely adopting a ⁇ -sheet configuration, connected by three hypervariable regions, which form loops connecting, and in some cases forming part of, the ⁇ -sheet structure.
  • the hypervariable regions in each chain are held together in close proximity by the FRs and, with the hypervariable regions from the other chain, contribute to the formation of the antigen-binding site of antibodies (see Kabat et al, Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)).
  • the constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody dependent cellular cytotoxicity (ADCC).
  • hypervariable region when used herein refers to the amino acid residues of an antibody which are responsible for antigen-binding.
  • the hypervariable region generally comprises amino acid residues from a "complementarity determining region" or "CDR" (e.g. around about residues 24-34 (Ll), 50-56 (L2) and 89-97 (L3) in the V L , and around about 31-35B (Hl), 50-65 (H2) and 95-102 (H3) in the V H (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)) and/or those residues from a
  • CDR complementarity determining region
  • hypervariable loop e.g. residues 26-32 (Ll), 50-52 (L2) and 91-96 (L3) in the V L , and 26-32 (Hl), 52A-55 (H2) and 96-101 (H3) in the V H (Chothia and Lesk J. MoI. Biol. 196:901-917 (1987)).
  • the "consensus sequence" or consensus V domain sequence is an artificial sequence derived from a comparison of the amino acid sequences of known human immunoglobulin variable region sequences. Based on these comparisons, recombinant nucleic acid sequences encoding the V domain amino acids that are a consensus of the sequences derived from the human K and the human H chain subgroup III V domains were prepared. The consensus V sequence does not have any known antibody binding specificity or affinity.
  • “Chimeric” antibodies have a portion of the heavy and/or light chain identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U.S. Patent No. 4,816,567; and Morrison et al, Proc. Natl. Acad. ScL USA 81 :6851-6855 (1984)).
  • Humanized antibody as used herein is a subset of chimeric antibodies.
  • Humanized forms of non-human ⁇ e.g., murine antibodies are chimeric antibodies which contain minimal sequence derived from non-human immunoglobulin.
  • humanized antibodies are human immunoglobulins (recipient or acceptor antibody) in which hypervariable region residues of the recipient are replaced by hypervariable region residues from a non-human species (donor antibody) such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity, and capacity.
  • donor antibody such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity, and capacity.
  • Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues.
  • humanized antibodies may comprise residues which are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance such as binding affinity.
  • the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence although the FR regions may include one or more amino acid substitutions that improve binding affinity.
  • the number of these amino acid substitutions in the FR are typically no more than 6 in the H chain, and in the L chain, no more than 3.
  • the humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
  • Fc immunoglobulin constant region
  • Antibody effector functions refer to those biological activities attributable to the Fc region (a native sequence Fc region or amino acid sequence variant Fc region) of an antibody, and vary with the antibody isotype. Examples of antibody effector functions include: CIq binding and complement dependent cytotoxicity; Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors ⁇ e.g. B cell receptor); and B cell activation.
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • FcRs Fc receptors
  • cytotoxic cells ⁇ e.g. Natural Killer (NK) cells, neutrophils, and macrophages
  • NK Natural Killer
  • the antibodies “arm” the cytotoxic cells and are absolutely required for such killing.
  • ADCC activity of a molecule of interest is assessed in vivo, e.g., in a animal model such as that disclosed in Clynes et al. PNAS (USA) 95:652-656 (1998).
  • Fc receptor or “FcR” describes a receptor that binds to the Fc region of an antibody.
  • the preferred FcR is a native sequence human FcR.
  • a preferred FcR is one which binds an IgG antibody (a gamma receptor) and includes receptors of the Fc ⁇ RI, Fc ⁇ RII, and Fc ⁇ RIII subclasses, including allelic variants and alternatively spliced forms of these receptors.
  • Fc ⁇ RII receptors include Fc ⁇ RIIA (an “activating receptor”) and Fc ⁇ RIIB (an “inhibiting receptor”), which have similar amino acid sequences that differ primarily in the cytoplasmic domains thereof.
  • Activating receptor Fc ⁇ RIIA contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain.
  • Inhibiting receptor Fc ⁇ RIIB contains an immunoreceptor tyrosine- based inhibition motif (ITIM) in its cytoplasmic domain, (see review M. in Daeron, Annu. Rev. Immunol. 15:203-234 (1997)).
  • FcRs are reviewed in Ravetch and Kinet, Annu. Rev. Immunol 9:457-92 (1991); Capel et al, Immunomethods 4:25-34 (1994); and de Haas et al, J. Lab. Clin. Med. 126:330-41 (1995).
  • FcR FcR
  • FcRn neonatal receptor
  • WO00/42072 Presta
  • WO 2004/056312 Lowman et al.
  • “Complement dependent cytotoxicity” or “CDC” refers to the lysis of a target cell in the presence of complement. Activation of the classical complement pathway is initiated by the binding of the first component of the complement system (CIq) to antibodies (of the appropriate subclass) which are bound to their cognate antigen.
  • CIq first component of the complement system
  • a CDC assay e.g. as described in Gazzano-Santoro et al., J. Immunol. Methods 202:163 (1996), may be performed.
  • Polypeptide variants with altered Fc region amino acid sequences and increased or decreased CIq binding capability are described in US patent No. 6,194,551Bl, WO99/51642. The contents of those patent publications are specifically incorporated herein by reference. See, also, Idusogie et al. J. Immunol. 164: 4178-4184 (2000).
  • naked antibody is an antibody (as herein defined) that is not conjugated to a heterologous molecule, such as a cytotoxic moiety, polymer, or radiolabel.
  • an “isolated” antibody is one that has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials that would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or non- proteinaceous solutes.
  • the antibody will be purified (1) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain.
  • Isolated antibody includes the antibody in situ within recombinant cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step.
  • Joint damage is used in the broadest sense and refers to damage or partial or complete destruction to any part of one or more joints, including the connective tissue and cartilage, where damage includes structural and/or functional damage of any cause, and may or may not cause joint pain/arthalgia. It specifically includes, without limitation, joint damage associated with or resulting from inflammatory joint disease as well as non- inflammatory joint disease.
  • This damage may be caused, for example, an autoimmune disease such as lupus ⁇ e.g., systemic lupus erythematosus), arthritis ⁇ e.g., acute and chronic arthritis, rheumatoid arthritis including juvenile-onset rheumatoid arthritis, juvenile idiopathic arthritis (JIA), or juvenile RA (JRA), and stages such as rheumatoid synovitis, gout or gouty arthritis, acute immunological arthritis, chronic inflammatory arthritis, degenerative arthritis, type II collagen-induced arthritis, infectious arthritis, septic arthritis, Lyme arthritis, proliferative arthritis, psoriatic arthritis, Still's disease, vertebral arthritis, osteoarthritis, arthritis chronica progrediente, arthritis deformans, polyarthritis chronica primaria, reactive arthritis, menopausal arthritis, estrogen-depletion arthritis, and ankylosing spondylitis/rheumatoid spondylitis), rheumatic
  • immunosuppressive agent refers to substances that act to suppress or mask the immune system of the mammal being treated herein. This would include substances that suppress cytokine production, down-regulate or suppress self-antigen expression, or mask the MHC antigens. Examples of such agents include 2-amino-6-aryl-5-substituted pyrimidines (see U.S. Pat. No.
  • non-steroidal anti-inflammatory drugs NSAIDs
  • ganciclovir tacrolimus, glucocorticoids such as Cortisol or aldosterone
  • anti-inflammatory agents such as a cyclooxygenase inhibitor, a 5-lipoxygenase inhibitor, or a leukotriene receptor antagonist
  • purine antagonists such as azathioprine or mycophenolate mofetil (MMF)
  • alkylating agents such as cyclophosphamide; bromocryptine; danazol; dapsone; glutaraldehyde (which masks the MHC antigens, as described in U.S. Pat. No.
  • anti- idiotypic antibodies for MHC antigens and MHC fragments include cyclosporin A; steroids such as corticosteroids or glucocorticosteroids or glucocorticoid analogs, e.g., prednisone, methylprednisolone, including SOLU- MEDROL ® methylpredniso lone sodium succinate, and dexamethasone; dihydrofolate reductase inhibitors such as methotrexate (oral or subcutaneous); anti-malarial agents such as chloroquine and hydroxychloroquine; sulfasalazine; leflunomide; cytokine antagonists such as cytokine antibodies or cytokine receptor antibodies including anti-interferon-alpha, -beta, or - gamma antibodies, anti-tumor necrosis factor (TNF)-alpha antibodies (infliximab (REMICADE®) or adalim
  • steroids such as
  • T- cell receptor fragments Offher et al, Science, 251: 430-432 (1991); WO 90/11294; Ianeway, Nature, 341 : 482 (1989); and WO 91/01133
  • BAFF antagonists such as BAFF antibodies and BR3 antibodies and zTNF4 antagonists (for review, see Mackay and Mackay, Trends Immunol., 23:113-5 (2002))
  • biologic agents that interfere with T cell helper signals such as anti-CD40 receptor or anti-CD40 ligand (CD 154), including blocking antibodies to CD40-CD40 ligand (e.g., Durie et al, Science, 261 : 1328-30 (1993); Mohan et al, J.
  • Some immunosuppressive agents herein are also DMARDs, such as methotrexate. Examples of preferred immunosuppressive agents herein include cyclophosphamide, chlorambucil, azathioprine, leflunomide, MMF, or methotrexate.
  • DMARDs Disease-modifying anti-rheumatic drugs
  • examples of “disease-modifying anti-rheumatic drugs” or “DMARDs” include hydroxycloroquine, sulfasalazine, methotrexate, leflunomide, etanercept, infliximab (plus oral and subcutaneous methotrexate), azathioprine, D-penicillamine, gold salts (oral), gold salts (intramuscular), minocycline, cyclosporine including cyclosporine A and topical cyclosporine, staphylococcal protein A (Goodyear and Silverman, J. Exp. Med., 197, (9), pi 125-39 (2003)), including salts and derivatives thereof, etc.
  • a preferred DMARD herein is methotrexate.
  • non-steroidal anti- inflammatory drugs or 'TSfSAIDs
  • examples of “non-steroidal anti- inflammatory drugs” or 'TSfSAIDs” include aspirin, acetylsalicylic acid, ibuprofen, flurbiprofen, naproxen, indomethacin, sulindac, tolmetin, phenylbutazone, diclofenac, ketoprofen, benorylate, mefenamic acid, methotrexate, fenbufen, azapropazone; COX-2 inhibitors such as celecoxib (CELEBREX® ; 4-(5 -(4-methylphenyl)-3 -(trifiuoromethyl)- 1 H-pyrazo 1- 1 -yl) benzenesulfonamide, valdecoxib (BEXTRA®), meloxicam (MOBIC®), GR 253035 (Glaxo Wellcome); and MK966 (
  • integrin antagonists or antibodies include an LFA-I antibody, such as efalizumab (RAPTIV A ® ) commercially available from Genentech, or an alpha 4 integrin antibody such as natalizumab (ANTEGREN ® ) available from Biogen, or diazacyclic phenylalanine derivatives (WO 2003/89410), phenylalanine derivatives (WO 2003/70709, WO 2002/28830, WO 2002/16329 and WO 2003/53926), phenylpropionic acid derivatives (WO 2003/10135), enamine derivatives (WO 2001/79173), propanoic acid derivatives (WO 2000/37444), alkanoic acid derivatives (WO 2000/32575), substituted phenyl derivatives (US Pat.
  • LFA-I antibody such as efalizumab (RAPTIV A ® ) commercially available from Genentech
  • alpha 4 integrin antibody such as natalizumab (ANTEGREN ® ) available
  • Corticosteroid refers to any one of several synthetic or naturally occurring substances with the general chemical structure of steroids that mimic or augment the effects of the naturally occurring corticosteroids.
  • synthetic corticosteroids include prednisone, prednisolone (including methylprednisolone, such as SOLU- MEDROL ® methylprednisolone sodium succinate), dexamethasone or dexamethasone triamcinolone, hydrocortisone, and betamethasone.
  • the preferred corticosteroids herein are prednisone, methylprednisolone, hydrocortisone, or dexamethasone.
  • TNF drugs for the treatment of rheumatoid arthritis include molecules that target TNF ⁇ ligand, as well as molecules that target the receptors for TNF- TNF ⁇ namely TNFR-I and TNFR-2.
  • TNF-alpha tumor necrosis factor alpha
  • TNF-alpha refers to a human TNF-alpha molecule comprising the amino acid sequence as described in Pennica et al, Nature, 312:721 (1984) or Aggarwal et al, JBC, 260:2345 (1985).
  • a “TNF ⁇ inhibitor” or a “TNF ⁇ antagonist” herein is an agent that inhibits, to some extent, a biological function of TNF ⁇ , generally through binding to TNF ⁇ or to the receptors of TNF ⁇ , and neutralizing the activity of TNF ⁇ .
  • TNF inhibitors specifically contemplated herein are Etanercept (ENBREL®)), Infliximab (REMICADE®) and Adalimumab (HUMIRATM).
  • the term "inadequate response to a TNF ⁇ -inhibitor” refers to an inadequate response to previous or current treatment with a TNF ⁇ -inhibitor because of toxicity and/or inadequate efficacy.
  • the inadequate response can be assessed by a clinician skilled in treating the disease in question.
  • a mammal who experiences "toxicity" from previous or current treatment with the TNF ⁇ -inhibitor experiences one or more negative side-effects associated therewith such as infection (especially serious infections), congestive heart failure, demyelination (leading to multiple sclerosis), hypersensitivity, neurologic events, autoimmunity, non-Hodgkin's lymphoma, tuberculosis (TB), autoantibodies, etc.
  • a mammal who experiences "inadequate efficacy" continues to have active disease following previous or current treatment with a TNF ⁇ -inhibitor. For instance, the patient may have active disease activity after 1 month or 3 months of therapy with the TNF ⁇ -inhibitor.
  • a "package insert” is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, contraindications, other therapeutic products to be combined with the packaged product, and/or warnings concerning the use of such therapeutic products, etc.
  • a “medicament” is an active drug to treat the joint damage or its symptoms or side effects.
  • relapse is used herein the refer to the return of signs and symptoms of a disease after a patient has enjoyed a remission.
  • the target disease and/or various characteristics or symptoms of the disease were alleviated or healed, or progression of the disease was halted or slowed down, and subsequently the disease or one or more characteristics of the disease return, the patient is referred to as being "relapsed.”
  • Symptoms of rheumatoid arthritis include any of the symptoms listed in the 2000 revised American Rheumatoid Association criteria for the classification of rheumatoid arthritis, such as, for example, joint swelling, joint damage, bone deformity, bone erosion, pain, inflammation, and systemic effects associated with more advance forms of rheumatoid arthritis, including hypoalbuminemia and anemia of chronic disease.
  • the patient is considered to be relapsed, if one or more of these symptoms return, following initial successful treatment.
  • the present invention concerns a new mode of administration of CD20 antagonists to human subjects to treat an autoimmune disease.
  • the invention concerns a new treatment protocol for the administration of CD20 antibodies to treat an autoimmune disease, such as a chronic CD20-associated autoimmune disease, e.g. rheumatoid arthritis (RA) or lupus.
  • a chronic CD20-associated autoimmune disease e.g. rheumatoid arthritis (RA) or lupus.
  • RA rheumatoid arthritis
  • the treatment protocol of the present invention comprises, consists essentially of or consist of the administration of a full effective dose at the outset in the form of an i.v injection.
  • an effective amount of the CD20 antagonist such as a CD20 antibody
  • a first single intravenous (i.v.) infusion of the full dosage at the beginning of the treatment optionally followed by a second i.v. infusion of a full effective dose (usually but, not necessarily, essentially the same dosage as the first one) about 3 to 7 months, typically about 4 to 6 months following the first administration.
  • a full effective dose usually but, not necessarily, essentially the same dosage as the first one
  • the second i.v. administration takes place usually 6 month after the initial treatment.
  • the timing of the second administration might vary depending on the nature and stage of the autoimmune disease to be treated, and the patient's response to the initial treatment which might vary from individual to individual. While the second effective dose is typically the same as the first one, it might be greater or smaller, depending on the patient's response to the first treatment, and the resultant change in the patient's condition.
  • CD20 antibodies include: “C2B8,” which is now called “rituximab” ("RITUXAN®”) (US Patent No. 5,736,137); the yttrium-[90]-labelled 2B8 murine antibody designated “Y2B8” or “Ibritumomab Tiuxetan” (ZEV ALIN®) commercially available from IDEC Pharmaceuticals, Inc. (US Patent No. 5,736,137; 2B8 deposited with ATCC under accession no.
  • A20 antibody or variants thereof such as chimeric or humanized A20 antibody (cA20, hA20, respectively) (US 2003/0219433, Immunomedics); and monoclonal antibodies L27, G28-2, 93-1B3, B-Cl or NU-B2 available from the International Leukocyte Typing Workshop (Valentine et al., In: Leukocyte Typing III (McMichael, Ed., p. 440, Oxford University Press (1987)).
  • the preferred CD20 antibodies herein are humanized, chimeric, or human CD20 antibodies, more preferably, a humanized 2H7 antibody, rituximab, chimeric or humanized A20 antibody (Immunomedics), and HUMAX-CD20TM human CD20 antibody (Genmab).
  • a humanized antibody that binds human CD20 and preferably other primate CD20 as well, will comprise a heavy (H) chain having at least one, preferably two or all of the H chain CDRs of a non-human species anti-human CD20 antibody (donor antibody), and substantially all of the framework residues of a human consensus antibody as the recipient antibody.
  • the donor antibody can be from various non-human species including mouse, rat, guinea pig, goat, rabbit, horse, primate but most frequently will be a murine antibody.
  • “Substantially all” in this context is meant that the recipient FR regions in the humanized antibody may include one or more amino acid substitutions not originally present in the human consensus FR sequence. These FR changes may comprise residues not found in the recipient or the donor antibody.
  • the donor antibody is the murine 2H7 antibody, the V region including the CDR and FR sequences of each of the H and L chains of which are shown in Figure IA and IB.
  • the residues for the human Fab framework correspond to the consensus sequence of human VK subgroup I and of V H subgroup III , these consensus sequences are shown in Figure IA and Figure IB, respectively.
  • the humanized 2H7 antibody of the invention will have at least one of the CDRs in the H chain of the murine donor antibody.
  • the humanized 2H7 antibody that binds human CD20 comprises the CDRs of both the H and L chains of the donor antibody.
  • the humanized CD20 binding antibody of the invention will comprise a humanized V domain joined to a C domain of a human immunoglobulin.
  • the H chain C region is from human IgG, preferably IgGl or IgG3.
  • the L chain C domain is preferably from human K chain.
  • a CD20 binding antibody composition useful in this invention can comprise antibody with K447, with all K447 removed, or a mixture of antibody with and without the K447 residue.
  • the humanized 2H7 antibody is an antibody listed in Table 1.
  • Each of the antibody variants A, B and I of Table 1 comprises the light chain variable sequence (VL): DIQMTQSPSSLSASVGDRVTITCRASSSVSYMHWYQQKPGKAPKPLIYAP
  • Each of the antibody variants C, D, F and G of Table 1 comprises the light chain variable sequence (VL):
  • the antibody variant H of Table 1 comprises the light chain variable sequence (V L ) of SEQ ID NO:3 (above) and the heavy chain variable sequence (V H ):
  • Each of the antibody variants A, B and I of Table 1 comprises the full length light chain sequence: DIQMTQSPSSLSASVGDRVTITCRASSSVSYMHWYQQKPGKAPKPLIYAP SNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSFNPPTFGQGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQE SVTEQDSKDSTYSLSSTLTLSKAD YEKHKVY ACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:6).
  • Variant A of Table 1 comprises the full length heavy chain sequence: EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHWVRQAPGKGLEWV GAIYPGNGDTSYNQKFKGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARVVY YSNSYWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYF PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHK PSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVVLTVLHQDW LNGKEYKCKVSNKALP APIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPEN
  • Variant I of Table 1 comprises the full length heavy chain sequence: EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHWVRQAPGKGLEWV GAIYPGNGDTSYNQKFKGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARVVY YSNSYWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYF PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHK PSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNATYRVVSVLTVLHQD WLNGKEYKCKVSNAALP APIAATISKAKGQPREPQVYTLPPSREEMTKNQVSLT CLVKGFYPSDIAVEWESNGQ
  • Variant B of Table 1 comprises the full length heavy chain sequence: EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHWVRQAPGKGLEWV GAIYPGNGDTSYNQKFKGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARVVY YSNSYWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYF PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHK PSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNATYRVVSVLTVLHQD WLNGKEYKCKVSNKALP APIAATISKAKGQPREPQVYTLPPSREEMTKNQVSLT CLVKGFYPSDIAVEWESNGQ
  • Variant C of Table 1 comprises the full length heavy chain sequence: EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHWVRQAPGKGLEWV GAIYPGNGATSYNQKFKGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARVVY YSASYWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYF PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHK PSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNATYRVVSVLTVLHQD WLNGKEYKCKVSNKALP APIAATISKAKGQPREPQVYTLPPSREEMTKNQVSLT CLVKGFYPSDIAVEWESNGQPEN
  • Variant D of Table 1 comprises the full length heavy chain sequence: EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHWVRQAPGKGLEWV GAIYPGNGATSYNQKFKGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARVVY YSASYWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYF PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHK PSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNATYRVVSVLTVLHQD WLNGKEYKCAVSNKALPAPIEATISKAKGQPREPQVYTLPPSREEMTKNQVSLT CLVKGFYPSDIAVEWESNGQPENNY
  • Variant F of Table 1 comprises the full length heavy chain sequence: EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHWVRQAPGKGLEWV GAIYPGNGATSYNQKFKGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARVVY YSASYWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYF PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHK PSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNATYRVVSVLTVLHQD WLNGKEYKCKVSNAALP APIAATISKAKGQPREPQVYTLPPSREEMTKNQVSLT CLVKGFYPSDIAVEWESNGQPEN
  • Variant G of Table 1 comprises the full length heavy chain sequence: EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHWVRQAPGKGLEWV GAIYPGNGATSYNQKFKGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARVVY YSASYWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYF PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHK PSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNATYRVVSVLTVLHQD WLNGKEYKCKVSNAALP APIAATISKAKGQPREPQVYTLPPSREEMTKNQVSLT CLVKGFYPSDIAVEWESNGQPEN
  • Variant H of Table 1 comprises the full length heavy chain sequence: EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHWVRQAPGKGLEWV GAIYPGNGATSYNQKFKGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARVVY YSYRYWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYF PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHK PSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNATYRVVSVLTVLHQD WLNGKEYKCKVSNAALP APIAATISKAKGQPREPQVYTLPPSREEMTKNQVSLT CLVKGFYPSDIAVEWESNGQPEN
  • the humanized 2H7 antibody of the invention further comprises amino acid alterations in the IgG Fc and exhibits increased binding affinity for human FcRn over an antibody having wild-type IgG Fc, by at least 60 fold, at least 70 fold, at least 80 fold, more preferably at least 100 fold, preferably at least 125 fold, even more preferably at least 150 fold to about 170 fold.
  • Humanized 2H7 antibody compositions of the present invention include compositions of any of the preceding humanized 2H7 antibodies having a Fc region, wherein about 80-100% (and preferably about 90-99%) of the antibody in the composition comprises a mature core carbohydrate structure which lacks fucose, attached to the Fc region of the glycoprotein.
  • Such compositions were demonstrated herein to exhibit a surprising improvement in binding to Fc(RIIIA(F 158), which is not as effective as Fc(RIIIA (V 158) in interacting with human IgG.
  • Fc(RIIIA (F 158) is more common than Fc(RIIIA (V 158) in normal, healthy African Americans and Caucasians. See Lehrnbecher et al., Blood 94:4220 (1999).
  • CHO Chinese Hamster Ovary Cells
  • YB2/0 and Led 3 can produce antibodies with 78 to 98% nonfucosylated species.
  • Shinkawa et al, J Bio. Chem. 278 (5), 3466-347 (2003) reported that antibodies produced in YB2/0 and Lee 13 cells, which have less FUT8 activity, show significantly increased ADCC activity in vitro.
  • CD20 binding antibodies encompass bispecific CD20 binding antibodies wherein one arm of the antibody has a heavy (H) and a light (L) chain of a CD20 binding antibody such as a H and L chain of the humanized 2H7 antibody of the invention, and the other arm has V region binding specificity for a second antigen.
  • the second antigen is selected from the group consisting of CD3, CD64, CD32A, CD 16, NKG2D or other NK activating ligands.
  • the Genentech and Biogen pou clinical investigations have evaluated the therapeutic effectiveness of treatment of autoimmune diseases using doses of anti-CD20 (humanized 2H7 variant and Rituximab) ranging from as low as 10 mg up to a dose of 1 g (see under Background section for Rituximab studies; and WO 04/056312, Example 16).
  • the antibodies were administered in these clinical investigations in two doses, spaced about two weeks apart.
  • Examples of regimens studied in the clinical investigations include, for humanized CD20 antibody 2H7 in rheumatoid arthritis at 2 x 10 mg (means 2 doses at lOmg per dose; total dose of ⁇ 10.1mg/m 2 for a 70 kg, 67 inch tall patient), 2 x 50 mg (total dose of 55 mg/m 2 for a 70 kg, 67 in tall patient), 2 x 200 mg (total dose of 220 mg/m 2 for a 70 kg, 67 in tall patient), 2 x 500 mg (total dose of -550 mg/m2 for a 70 kg, 67 in tall patient) and 2 x 1000 mg (total dose of ⁇ 1100 mg/m2 for a 70 kg, 67 in tall patient ); and for Rituxan, 2 x 500 mg (total dose of -550 mg/m2 for a 70 kg, 67 in tall patient), 2 x 1000 mg (total dose of -1100 mg/m2 for a 70 kg, 67 in tall patient).
  • the therapeutic effectiveness of treatment of autoimmune diseases has been evaluated using doses of CD20 antibody ranging from as low as 1 mg up to a dose of 2 g . Since, as shown in the Example, the single infusion treatment showed similar results for all dosages tested (400 mg, 1000 mg, 1500 mg and 2000 mg), the effective dose might vary within a wide range and typically is between about 0.1 mg and about 2000 mg, or between about 1 mg and about 2000 mg, or between about 10 mg and 2000 mg, or between about 400 mg and 2000 mg of the CD20 antibody. The effective dose varies depending on the CD20 antibody used, the disease treated, including the severity of the disease, the patient's sex, weight, age and overall physical condition, and other factors, usually considered by practicing physicians.
  • the CD20 antibody can be administered at dosages of 0.1, 0.5, 1, 5, 10, 15, 20 25, 30, 40, 50, 75, 100, 125, 150, 200, 250, 300, 350, 400, 500, 1000, 1500, or 2000 mg.
  • the parameters for assessing efficacy or success of treatment of an autoimmune or autoimmune related disease will be known to the physician of skill in the appropriate disease. Generally, the physician of skill will look for reduction in the signs and symptoms of the specific disease.
  • B cell depletion can but does not have to be complete. Or, total B cell depletion may be desired in initial treatment but in subsequent treatments, the dosage may be adjusted to achieve only partial depletion.
  • the B cell depletion is at least 20%, i.e., 80% or less of CD20 positive B cells remain as compared to the baseline level before treatment. In other embodiments, B cell depletion is 25%, 30%, 40%, 50%, 60%, 70% or greater.
  • the B cell depletion is sufficient to halt progression of the disease, more preferably to alleviate the signs and symptoms of the particular disease under treatment, even more preferably to cure the disease.
  • Lower CD20 dosages e.g., at 20 mg, 10 mg or lower, can be used if partial or short term B cell depletion is the objective, or if the disease is not chronic or less severe.
  • treatment at the low dosages of the present invention is useful in maintenance therapy, following successful treatment with an initial higher dosage, administered in accordance with the present invention.
  • the first administration of a complete effective dose as a single i.v. infusion is followed by the i.v.
  • infusion is the same dose 4 to 6 months after the first administration, which may be followed by the administration of lower maintenance dosages, typically in 4 to 6 months intervals.
  • Patients having an autoimmune disease for whom one or more current standard of care therapies were ineffective, poorly tolerated, or contraindicated can be treated using the dosing regimens of the present invention.
  • the invention contemplates the present treatment methods for RA patients who have had an inadequate response to tumor necrosis factor (TNF) inhibitor therapies or to disease-modifying anti-rheumatic drugs (DMARD) therapy.
  • TNF tumor necrosis factor
  • DMARD disease-modifying anti-rheumatic drugs
  • the present dosages and dosing regimen are used in treating rheumatoid arthritis (RA), such as active RA, e.g. moderate to severe active RA.
  • RA rheumatoid arthritis
  • RA is a debilitating autoimmune disease that affects more than two million Americans and hinders the daily activities of sufferers. RA occurs when the body's own immune system inappropriately attacks joint tissue and causes chronic inflammation that destroys healthy tissue and damage within the joints. Symptoms include inflammation of the joints, swelling, stiffness, and pain. Additionally, since RA is a systemic disease, it can have effects in other tissues such as the lungs, eyes and bone marrow. At present, there is no known cure for RA. Current treatments include a variety of steroidal and non-steroidal anti- inflammatory drugs, immunosuppressive agents, disease-modifying anti-rheumatic drugs (DMARDs), and biologies. However, many patients continue to have an inadequate response to such treatments.
  • DMARDs disease-modifying anti-rheumatic drugs
  • the CD20 antibodies can be used as first-line therapy in patients with early RA (i.e., methotrexate (MTX) naive) and as monotherapy, or in combination with, e.g., MTX or cyclophosphamide. Or, the antibodies can be used in treatment as second-line therapy for patients who were DMARD and/or MTX refractory, and as monotherapy or in combination with other drug therapies, e.g., MTX.
  • the humanized CD20 binding antibodies are useful to prevent and control joint damage, delay structural damage, decrease pain associated with inflammation in RA, and generally reduce the signs and symptoms in active RA, such as moderate to severe RA.
  • the RA patient can be treated with the humanized CD20 antibody prior to, after or together with treatment with other drugs used in treating RA (see combination therapy below).
  • patients who had previously failed disease-modifying antirheumatic drugs and/or had an inadequate response to methotrexate alone are treated with a humanized CD20 binding antibody herein.
  • the patients initially receive a humanized CD20 binding antibody alone, following the dosing regimen of the present invention, followed by the administration of the CD20 antibody plus cyclophosphamide, or CD20 antibody plus methotrexate.
  • ACR American College of Rheumatology
  • the RA patient can be scored at for example, ACR 20 (20 percent improvement) compared with no antibody treatment (e.g,, baseline before treatment) or treatment with placebo.
  • Other ways of evaluating the efficacy of antibody treatment include X-ray scoring such as the Sharp X-ray score used to score structural damage such as bone erosion and joint space narrowing.
  • Patients can also be evaluated for the prevention of or improvement in disability based on Health Assessment Questionnaire [HAQ] score, AIMS score, SF-36 at time periods during or after treatment.
  • the ACR 20 criteria may include 20% improvement in both tender (painful) joint count and swollen joint count plus a 20% improvement in at least 3 of 5 additional measures:
  • VAS visual analog scale
  • VAS patient's global assessment of disease activity
  • VAS physician's global assessment of disease activity
  • the ACR 50 and 70 are defined analogously.
  • the patient is administered an amount of a CD20 antibody of the invention effective to achieve at least a score of ACR 20, preferably at least ACR 30, more preferably at least ACR50, even more preferably at least ACR70, most preferably at least ACR 75 and higher.
  • Psoriatic arthritis has unique and distinct radiographic features.
  • joint erosion and joint space narrowing can be evaluated by the Sharp score as well.
  • the humanized CD20 binding antibodies of the invention can be used to prevent the joint damage as well as reduce disease signs and symptoms of the disorder.
  • Yet another aspect of the invention is a method of treating Lupus or SLE by administering to the patient suffering from SLE, a therapeutically effective amount of a humanized CD20 antibody of the invention.
  • SLE patients include patients with extrarenal manifestations as well as with lupus nephritis.
  • SLEDAI scores provide a numerical quantitation of disease activity.
  • the SLEDAI is a weighted index of 24 clinical and laboratory parameters known to correlate with disease activity, with a numerical range of 0-103. see Bryan Gescuk & John Davis, "Novel therapeutic agent for systemic lupus erythematosus" in Current Opinion in Rheumatology 2002, 14:515-521.
  • Antibodies to double-stranded DNA are believed to cause renal flares and other manifestations of lupus.
  • Patients undergoing antibody treatment can be monitored for time to renal flare, which is defined as a significant, reproducible increase in serum creatinine, urine protein or blood in the urine.
  • patients can be monitored for levels of antinuclear antibodies and antibodies to double-stranded DNA.
  • Treatments for SLE include high-dose corticosteroids and/or cyclophosphamide (HDCC).
  • vasculitis With regard to vasculitis, approximately 75% of the patients with systemic vasculitides have anti-neutrophil cytoplasmic antibody and cluster into one of three conditions affecting small/medium sized vessels: Wegeners granulomatosus (WG), microscopic polyangiitis (MPA)and Churg Strauss syndrome (CSS), collectively known as ANCA associated vasculitis (AAV).
  • WG Wegeners granulomatosus
  • MPA microscopic polyangiitis
  • CSS Churg Strauss syndrome
  • AAV ANCA associated vasculitis
  • Spondyloarthropathies are a group of disorders of the joints, including ankylosing spondylitis, psoriatic arthritis and Crohn's disease. Treatment success can be determined by validated patient and physician global assessment measuring tools. Various medications are used to treat psoriasis; treatment differs directly in relation to disease severity. Patients with a more mild form of psoriasis typically utilize topical treatments, such as topical steroids, anthralin, calcipotriene, clobetasol, and tazarotene, to manage the disease while patients with moderate and severe psoriasis are more likely to employ systemic (methotrexate, retinoids, cyclosporine, PUVA and UVB) therapies.
  • topical treatments such as topical steroids, anthralin, calcipotriene, clobetasol, and tazarotene
  • Tars are also used. These therapies have a combination of safety concerns, time consuming regimens, or inconvenient processes of treatment. Furthermore, some require expensive equipment and dedicated space in the office setting. Systemic medications can produce serious side effects, including hypertension, hyperlipidemia, bone marrow suppression, liver disease, kidney disease and gastrointestinal upset. Also, the use of phototherapy can increase the incidence of skin cancers. In addition to the inconvenience and discomfort associated with the use of topical therapies, phototherapy and systemic treatments require cycling patients on and off therapy and monitoring lifetime exposure due to their side effects.
  • Treatment efficacy for psoriasis is assessed by monitoring changes in clinical signs and symptoms of the disease including Physician's Global Assessment (PGA) changes and Psoriasis Area and Severity Index (PASI) scores, Psoriasis Symptom Assessment (PSA), compared with the baseline condition.
  • PGA Physician's Global Assessment
  • PASI Psoriasis Area and Severity Index
  • PSA Psoriasis Symptom Assessment
  • the patient can be measured periodically throughout treatment on the Visual analog scale used to indicate the degree of itching experienced at specific time points.
  • Patients may experience an infusion reaction or infusion-related symptoms with their first infusion of a therapeutic antibody. These symptoms vary in severity and generally are reversible with medical intervention. These symptoms include but are not limited to, flu-like fever, chills/rigors, nausea, urticaria, headache, bronchospasm, angioedema.
  • the patient may receive an initial conditioning or tolerizing dose(s) of the antibody followed by a therapeutically effective dose.
  • the conditioning dose(s) will be lower than the therapeutically effective dose to condition the patient to tolerate higher dosages.
  • the patient can be treated with one or more CD20 binding antibodies in conjunction with a second therapeutic agent, such as an immunosuppressive agent, such as in a multi drug regimen.
  • the CD20 binding antibody can be administered concurrently, sequentially or alternating with the immunosuppressive agent or upon non-responsiveness with other therapy.
  • the immunosuppressive agent can be administered at the same or lesser dosages than as set forth in the art.
  • the preferred adjunct immunosuppressive agent will depend on many factors, including the type of disorder being treated as well as the patient's history.
  • "Immunosuppressive agent” as used herein for adjunct therapy refers to substances that act to suppress or mask the immune system of a patient. Such agents would include substances that suppress cytokine production, down regulate or suppress self-antigen expression, or mask the MHC antigens.
  • steroids such as glucocorticosteroids, e.g., prednisone, methylprednisolone, and dexamethasone; 2-amino-6-aryl-5-substituted pyrimidines (see U.S. Pat. No. 4,665,077), azathioprine (or cyclophosphamide, if there is an adverse reaction to azathioprine); bromocryptine; glutaraldehyde (which masks the MHC antigens, as described in U.S. Pat. No.
  • steroids such as glucocorticosteroids, e.g., prednisone, methylprednisolone, and dexamethasone
  • 2-amino-6-aryl-5-substituted pyrimidines see U.S. Pat. No. 4,665,077)
  • azathioprine or cyclophosphamide, if there is an adverse reaction to azathioprine
  • anti-idiotypic antibodies for MHC antigens and MHC fragments include cyclosporin A; cytokine or cytokine receptor antagonists including anti-interferon- ⁇ , - ⁇ , or - ⁇ antibodies; anti-tumor necrosis factor- ⁇ antibodies; anti-tumor necrosis factor- ⁇ antibodies; anti-interleukin-2 antibodies and anti-IL-2 receptor antibodies; anti-L3T4 antibodies; heterologous anti-lymphocyte globulin; pan-T antibodies, preferably anti- CD3 or anti-CD4/CD4a antibodies; soluble peptide containing a LFA-3 binding domain (WO 90/08187 published 7/26/90); streptokinase; TGF- ⁇ ; streptodornase; RNA or DNA from the host; FK506; RS-61443; deoxyspergualin; rapamycin; T-cell receptor (U.S.
  • T-cell receptor fragments (Offiier et al., Science 251 :430-432 (1991); WO 90/11294; and WO 91/01133); and T cell receptor antibodies (EP 340,109) such as T10B9.
  • the patient can be treated with a CD20 binding antibody (such as rituximab or ocrelizumab or variant thereof) in conjunction with any one or more of the following drugs: DMARDS (disease-modifying antirheumatic drugs (e.g., methotrexate), NSAI or NSAID (non-steroidal anti-inflammatory drugs), immunosuppressants (e.g., azathioprine; mycophenolate mofetil (CellCept®; Roche)), analgesics, glucocorticosteroids, cyclophosphamide, HUMIRATM (adalimumab; Abbott Laboratories), ARAV A® (leflunomide), REMICADE® (infliximab; Centocor Inc., of Malvern, Pa), ENBREL (etanercept; Immunex, WA),
  • DMARDS disease-modifying antirheumatic drugs (e.g., methotrexate), NSAI or NSAID (non
  • ACTEMRA tocilizumab; Roche, Switzerland
  • COX-2 inhibitors tocilizumab
  • DMARDs commonly used in RA are hydroxycloroquine, sulfasalazine, methotrexate, leflunomide, etanercept, infliximab, azathioprine, D-penicillamine, Gold (oral), Gold (intramuscular), minocycline, cyclosporine, Staphylococcal protein A immuno adsorption.
  • Adalimumab is a human monoclonal antibody that binds to TNFV.
  • Infliximab is a chimeric monoclonal antibody that binds to TNFV.
  • Etanercept is an "immunoadhesin" fusion protein consisting of the extracellular ligand binding portion of the human 75 kD (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of a human IgGl .
  • Actemra tocilizumab
  • IL-6 humanized anti-human interleukin-6 receptor
  • An exemplary dosage of MTX is about 7.5- 25 mg/kg/wk.
  • MTX can be administered orally and subcutaneously.
  • the patient can be treated with a CD20 binding antibody of the invention in conjunction with, for example, Remicade® (infliximab; from Centocor Inc., of Malvern, Pa.), ENBREL (etanercept; Immunex, WA).
  • Remicade® infliximab
  • Centocor Inc. Centocor Inc., of Malvern, Pa.
  • ENBREL etanercept; Immunex, WA.
  • Treatments for SLE include combination of the CD20 antibody with high-dose corticosteroids and/or cyclophosphamide (HDCC).
  • Patients suffering from SLE, AAV and NMO can be treated with a CD20 binding antibody of the invention in combination with any of the following: corticosteroids, NSAIDs, analgesics, COX-2 inhibitors, glucocorticosteriods, conventional DMARDS (e.g.
  • biologic DMARDs such as anti-Blys (e.g., belimumab), anti-IL6R e.g., tocilizumab; CTLA4-Ig (abatacept), (anti-CD22 e.g., epratuzumab), immunosuppressants (e.g., azathioprine; mycophenolate mofetil (CellCept®; Roche)), and cytotoxic agents (e.g., cyclophosphamide).
  • anti-Blys e.g., belimumab
  • anti-IL6R e.g., tocilizumab
  • CTLA4-Ig abatacept
  • anti-CD22 e.g., epratuzumab
  • immunosuppressants e.g., azathioprine; mycophenolate mofetil (CellCept®; Roche
  • cytotoxic agents e.g., cyclophosphamide
  • patients can be administered a CD20 binding antibody in conjunction with topical treatments, such as topical steroids, anthralin, calcipotriene, clobetasol, and tazarotene, or with methotrexate, retinoids, cyclosporine, PUVA and UVB therapies.
  • topical treatments such as topical steroids, anthralin, calcipotriene, clobetasol, and tazarotene, or with methotrexate, retinoids, cyclosporine, PUVA and UVB therapies.
  • topical treatments such as topical steroids, anthralin, calcipotriene, clobetasol, and tazarotene
  • methotrexate retinoids
  • cyclosporine PUVA and UVB therapies.
  • the traditional systemic therapies can be administered in rotational, sequential, combinatorial, or intermittent treatment regimens, or lower dosage combination regimens with the CD20 binding antibody compositions at the present dosages.
  • Therapeutic formulations of the CD20-binding antibodies used in accordance with the present invention are prepared for storage by mixing an antibody having the desired degree of purity with optional pharmaceutically acceptable carriers, excipients or stabilizers ⁇ Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions.
  • Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as olyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine
  • CD20 antigen to be used for production of, or screening for, antibody(ies) may be, e.g., a soluble form of CD20 or a portion thereof, containing the desired epitope.
  • cells expressing CD20 at their cell surface can be used to generate, or screen for, antibody(ies).
  • Other forms of CD20 useful for generating antibodies will be apparent to those skilled in the art.
  • a protein that is immunogenic in the species to be immunized e.g., keyhole limpet hemocyanin, serum albumin,
  • Animals are immunized against the antigen, immunogenic conjugates, or derivatives by combining, e.g., 100 ⁇ g or 5 ⁇ g of the protein or conjugate (for rabbits or mice, respectively) with 3 volumes of Freund's complete adjuvant and injecting the solution intradermally at multiple sites.
  • the animals are boosted with 1/5 to 1/10 the original amount of peptide or conjugate in Freund's complete adjuvant by subcutaneous injection at multiple sites.
  • Seven to 14 days later the animals are bled and the serum is assayed for antibody titer. Animals are boosted until the titer plateaus.
  • the animal is boosted with the conjugate of the same antigen, but conjugated to a different protein and/or through a different cross-linking reagent.
  • Conjugates also can be made in recombinant cell culture as protein fusions.
  • aggregating agents such as alum are suitably used to enhance the immune response.
  • Monoclonal antibodies are obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical and/or bind the same epitope except for possible variants that arise during production of the monoclonal antibody, such variants generally being present in minor amounts.
  • the modifier "monoclonal" indicates the character of the antibody as not being a mixture of discrete or polyclonal antibodies.
  • the monoclonal antibodies may be made using the hybridoma method first described by Kohler et al, Nature, 256:495 (1975), or may be made by recombinant DNA methods (U.S. Patent No. 4,816,567).
  • a mouse or other appropriate host animal such as a hamster
  • lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for immunization.
  • lymphocytes may be immunized in vitro. Lymphocytes then are fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice, pp.59-103 (Academic Press, 1986)).
  • the hybridoma cells thus prepared are seeded and grown in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells.
  • a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells.
  • the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT medium), which substances prevent the growth of HGPRT-deficient cells.
  • Preferred myeloma cells are those that fuse efficiently, support stable high-level production of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium.
  • preferred myeloma cell lines are murine myeloma lines, such as those derived from MOPC-21 and MPC-11 mouse tumors available from the SaIk Institute Cell Distribution Center, San Diego, California USA, and SP-2 or X63-Ag8-653 cells available from the American Type Culture Collection, Rockville, Maryland USA.
  • Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies
  • Culture medium in which hybridoma cells are growing is assayed for production of monoclonal antibodies directed against the antigen.
  • the binding specificity of monoclonal antibodies produced by hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA).
  • RIA radioimmunoassay
  • ELISA enzyme-linked immunoabsorbent assay
  • the binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson et al, Anal. Biochem., 107:220 (1980).
  • the clones may be subcloned by limiting dilution procedures and grown by standard methods (Goding, Monoclonal Antibodies: Principles and Practice, pp.59-103 (Academic Press, 1986)).
  • Suitable culture media for this purpose include, for example, D-MEM or RPMI- 1640 medium.
  • the hybridoma cells may be grown in vivo as ascites tumors in an animal.
  • the monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional immunoglobulin purification procedures such as, for example, protein A-SEPHAROSETM, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
  • DNA encoding the monoclonal antibodies is readily isolated and sequenced using conventional procedures ⁇ e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies).
  • the hybridoma cells serve as a preferred source of such DNA.
  • the DNA may be placed into expression vectors, which are then transfected into host cells such as E. coli cells, simian COS cells, Chinese Hamster Ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells.
  • antibodies or antibody fragments can be isolated from antibody phage libraries generated using the techniques described in McCafferty et ah, Nature, 348:552-554 (1990). Clackson et al, Nature, 352:624-628 (1991) and Marks et al, J. MoI. Biol, 222:581-597 (1991) describe the isolation of murine and human antibodies, respectively, using phage libraries.
  • the DNA also may be modified, for example, by substituting the coding sequence for human heavy- and light chain constant domains in place of the homologous murine sequences (U.S. Patent No. 4,816,567; Morrison, et al, Proc. Natl Acad. Sci. USA, 81 :6851 (1984)), or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide.
  • non-immunoglobulin polypeptides are substituted for the constant domains of an antibody, or they are substituted for the variable domains of one antigen- combining site of an antibody to create a chimeric bivalent antibody comprising one antigen-combining site having specificity for an antigen and another antigen-combining site having specificity for a different antigen.
  • antibodies comprising a variant Fc region with high affinity for Fc ⁇ R are useful for treating diseases where an enhanced efficacy of effector cell function is desired, such as autoimmune diseases, as set forth, for example, in US 2005/0037000 and WO 2004/63351 (Macrogenics, Inc. STAVENHAGEN et al).
  • a humanized antibody has one or more amino acid residues introduced into it from a source that is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import” variable domain.
  • Humanization can be essentially performed following the method of Winter and co-workers (Jones et al., Nature, 321 :522-525 (1986); Riechmann et al., Nature, 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)), by substituting hypervariable region sequences for the corresponding sequences of a human antibody.
  • humanized antibodies are chimeric antibodies (U.S. Patent No. 4,816,567) wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species.
  • humanized antibodies are typically human antibodies in which some hypervariable region residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.
  • variable domains both light and heavy
  • sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable-domain sequences.
  • the human sequence that is closest to that of the rodent is then accepted as the human framework region (FR) for the humanized antibody (Sims et al., J. Immunol. , 151 :2296 (1993); Chothia et al., J. MoI. Biol, 196:901 (1987)).
  • Another method uses a particular framework region derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chain variable regions.
  • humanized antibodies are prepared by a process of analysis of the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences. Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art. Computer programs are available that illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences.
  • human antibodies can be generated.
  • transgenic animals ⁇ e.g., mice
  • transgenic animals ⁇ e.g., mice
  • J H antibody heavy chain joining region
  • transfer of the human germ-line immunoglobulin gene array in such germ- line mutant mice will result in the production of human antibodies upon antigen challenge. See, e.g., Jakobovits et al, Proc. Natl Acad. Sci.
  • phage display technology can be used to produce human antibodies and antibody fragments in vitro, from immunoglobulin variable (V) domain gene repertoires from unimmunized donors.
  • V domain genes are cloned in-frame into either a major or minor coat protein gene of a filamentous bacteriophage, such as M13 or fd, and displayed as functional antibody fragments on the surface of the phage particle. Because the filamentous particle contains a single-stranded DNA copy of the phage genome, selections based on the functional properties of the antibody also result in selection of the gene encoding the antibody exhibiting those properties.
  • the phage mimics some of the properties of the B cell.
  • Phage display can be performed in a variety of formats; for their review see, e.g., Johnson et al, Current Opinion in Structural Biology 3:564-571 (1993).
  • V-gene segments can be used for phage display. Clackson et al, Nature, 352:624-628 (1991) isolated a diverse array of anti-oxazolone antibodies from a small random combinatorial library of V genes derived from the spleens of immunized mice.
  • a repertoire of V genes from unimmunized human donors can be constructed and antibodies to a diverse array of antigens (including self-antigens) can be isolated essentially following the techniques described by Marks et al., J. MoI. Biol. 222:581-597 (1991), or Griffith et al, EMBO J. 12:725-734 (1993). See, also, US Patent Nos. 5,565,332 and 5,573,905.
  • Human antibodies may also be generated by in vitro activated B cells (see US Patents 5,567,610 and 5,229,275).
  • Antibody fragments Various techniques have been developed for the production of antibody fragments. Traditionally, these fragments were derived via proteolytic digestion of intact antibodies (see, e.g., Morimoto et al, Journal of Biochemical and Biophysical Methods 24: 107-117 (1992) and Brennan et al, Science, 229:81 (1985)). However, these fragments can now be produced directly by recombinant host cells. For example, the antibody fragments can be isolated from the antibody phage libraries discussed above. Alternatively, Fab'-SH fragments can be directly recovered from E. coli and chemically coupled to form F(ab') 2 fragments (Carter et al, Bio/Technology 10: 163-167 (1992)).
  • F(ab') 2 fragments can be isolated directly from recombinant host cell culture.
  • the antibody of choice is a single chain Fv fragment (scFv). See WO 93/16185; US Patent No. 5,571,894; and US Patent No. 5,587,458.
  • the antibody fragment may also be a "linear antibody", e.g., as described in US Patent 5,641,870 for example. Such linear antibody fragments may be monospecific or bispecific. (vi) Bispecific antibodies
  • Bispecific antibodies are antibodies that have binding specificities for at least two different epitopes. Exemplary bispecific antibodies may bind to two different epitopes of the CD20 antigen. Other such antibodies may bind CD20 and further bind a second B- cell surface marker. Alternatively, an anti-CD20 binding arm may be combined with an arm that binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD2 or CD3), or Fc receptors for IgG (Fc ⁇ R), such as Fc ⁇ RI (CD64), Fc ⁇ RII (CD32) and Fc ⁇ RIII (CD 16) so as to focus cellular defense mechanisms to the B cell. Bispecific antibodies may also be used to localize certain agents to the B cell. These antibodies possess a CD20-binding arm and an arm that binds the agent (e.g. methotrexate). Bispecific antibodies can be prepared as full-length antibodies or antibody fragments (e.g. F(ab')2 bispecific antibodies).
  • bispecific antibodies are known in the art. Traditional production of full length bispecific antibodies is based on the co-expression of two immunoglobulin heavy chain-light chain pairs, where the two chains have different specificities (Millstein et al., Nature, 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of 10 different antibody molecules, of which only one has the correct bispecific structure. Purification of the correct molecule, which is usually done by affinity chromatography steps, is rather cumbersome, and the product yields are low. Similar procedures are disclosed in WO 93/08829, and in Traunecker et al, EMBO J, 10:3655-3659 (1991).
  • antibody variable domains with the desired binding specificities are fused to immunoglobulin constant domain sequences.
  • the fusion preferably is with an immunoglobulin heavy chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy chain constant region (CHl) containing the site necessary for light chain binding, present in at least one of the fusions.
  • DNAs encoding the immunoglobulin heavy chain fusions and, if desired, the immunoglobulin light chain are inserted into separate expression vectors, and are co-transfected into a suitable host organism.
  • the bispecific antibodies are composed of a hybrid immunoglobulin heavy chain with a first binding specificity in one arm, and a hybrid immunoglobulin heavy chain-light chain pair (providing a second binding specificity) in the other arm. It was found that this asymmetric structure facilitates the separation of the desired bispecific compound from unwanted immunoglobulin chain combinations, as the presence of an immunoglobulin light chain in only one half of the bispecific molecule provides for a facile way of separation. This approach is disclosed in WO 94/04690. For further details of generating bispecific antibodies see, for example, Suresh et ah, Methods in Enzymology, 121 :210 (1986).
  • the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers that are recovered from recombinant cell culture.
  • the preferred interface comprises at least a part of the C H 3 domain of an antibody constant domain.
  • one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. tyrosine or tryptophan).
  • Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.
  • Bispecific antibodies include cross-linked or "heteroconjugate" antibodies.
  • one of the antibodies in the heteroconjugate can be coupled to avidin, the other to biotin.
  • Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (US Patent No. 4,676,980), and for treatment of HIV infection (WO 91/00360, WO 92/200373, and EP 03089).
  • Heteroconjugate antibodies may be made using any convenient cross-linking methods. Suitable cross-linking agents are well known in the art, and are disclosed in US Patent No. 4,676,980, along with a number of cross-linking techniques.
  • bispecific antibodies can be prepared using chemical linkage.
  • Brennan et ah, Science, 229: 81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab')2 fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation.
  • the Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives.
  • One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody.
  • the bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.
  • bispecific antibodies have been produced using leucine zippers.
  • the leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion.
  • the antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers.
  • the fragments comprise a heavy chain variable domain (V H ) connected to a light chain variable domain (V L ) by a linker that is too short to allow pairing between the two domains on the same chain. Accordingly, the V H and V L domains of one fragment are forced to pair with the complementary V L and V H domains of another fragment, thereby forming two antigen-binding sites.
  • V H and V L domains of one fragment are forced to pair with the complementary V L and V H domains of another fragment, thereby forming two antigen-binding sites.
  • sFv single-chain Fv
  • Antibodies with more than two valencies are contemplated.
  • trispecific antibodies can be prepared. Tutt et al, J. Immunol. 147: 60 (1991).
  • the antibody may be conjugated to another molecule, for example, to increase half- life or stability or otherwise improve the pharmacokinetics of the antibody.
  • the antibody may be linked to one of a variety of non-proteinaceous polymers, e.g., polyethylene glycol (PEG), polypropylene glycol, polyoxyalkylenes, or copolymers of polyethylene glycol and polypropylene glycol.
  • PEG polyethylene glycol
  • Antibody fragments, such as Fab', linked to one or more PEG molecules are an especially preferred embodiment of the invention.
  • the antibodies disclosed herein may also be formulated as liposomes.
  • Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein et al, Proc. Natl. Acad. ScL USA, 82:3688 (1985); Hwang et al, Proc. Natl. Acad. Sci. USA, 77:4030 (1980); U.S. Pat. Nos. 4,485,045 and 4,544,545; and WO 97/38731 published October 23, 1997. Liposomes with enhanced circulation time are disclosed in U.S. Patent No. 5,013,556.
  • Particularly useful liposomes can be generated by the reverse phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol and PEG- derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter.
  • Fab' fragments of an antibody of the present invention can be conjugated to the liposomes as described in Martin et al. J. Biol. Chem. 257: 286-288 (1982) via a disulfide interchange reaction.
  • Amino acid sequence modification(s) of protein or peptide antibodies described herein are contemplated. For example, it may be desirable to improve the binding affinity and/or other biological properties of the antibody.
  • Amino acid sequence variants of the antibody are prepared by introducing appropriate nucleotide changes into the antibody nucleic acid, or by peptide synthesis. Such modifications include, for example, deletions from, and/or insertions into and/or substitutions of, residues within the amino acid sequences of the antibody. Any combination of deletion, insertion, and substitution is made to arrive at the final construct, provided that the final construct possesses the desired characteristics.
  • the amino acid changes also may alter post-translational processes of the antibody, such as changing the number or position of glycosylation sites.
  • a useful method for identification of certain residues or regions of the antibody that are preferred locations for mutagenesis is called "alanine scanning mutagenesis" as described by Cunningham and Wells, Science, 244:1081-1085 (1989).
  • a residue or group of target residues are identified ⁇ e.g., charged residues such as arg, asp, his, lys, and glu) and replaced by a neutral or negatively charged amino acid (most preferably alanine or polyalanine) to affect the interaction of the amino acids with antigen.
  • Those amino acid locations demonstrating functional sensitivity to the substitutions then are refined by introducing further or other variants at, or for, the sites of substitution.
  • the site for introducing an amino acid sequence variation is predetermined, the nature of the mutation per se need not be predetermined. For example, to analyze the performance of a mutation at a given site, ala scanning or random mutagenesis is conducted at the target codon or region and the expressed antibody variants are screened for the desired activity.
  • Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues.
  • terminal insertions include an antibody with an N-terminal methionyl residue or the antibody fused to a polypeptide or polymer.
  • Other insertional variants of the antibody molecule include the fusion to the N- or C-terminus of the antibody of an enzyme, or a polypeptide that increases the serum half-life of the antibody.
  • Another type of variant is an amino acid substitution variant. These variants have at least one amino acid residue in the antibody molecule replaced by different residue.
  • substitutional mutagenesis of antibodies include the hypervariable regions, but FR alterations are also contemplated.
  • Conservative substitutions are shown in the table below under the heading of "preferred substitutions". If such substitutions result in a change in biological activity, then more substantial changes, denominated "exemplary substitutions" in the table below, or as further described below in reference to amino acid classes, may be introduced and the products screened.
  • Substantial modifications in the biological properties of the antibody are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.
  • Amino acids may be grouped according to similarities in the properties of their side chains (in A. L. Lehninger, in Biochemistry, second ed., pp. 73-75, Worth Publishers, New York (1975)):
  • non-polar Ala (A), VaI (V), Leu (L), He (I), Pro (P), Phe (F), Trp (W), Met (M)
  • uncharged polar GIy (G), Ser (S), Thr (T), Cys (C), Tyr (Y), Asn (N), GIn
  • Non-conservative substitutions will entail exchanging a member of one of these classes for another class. Any cysteine residue not involved in maintaining the proper conformation of the antibody also may be substituted, generally with serine, to improve the oxidative stability of the molecule and prevent aberrant crosslinking. Conversely, cysteine bond(s) may be added to the antibody to improve its stability (particularly where the antibody is an antibody fragment such as an Fv fragment).
  • a particularly preferred type of substitutional variant involves substituting one or more hypervariable region residues of a parent antibody. Generally, the resulting variant(s) selected for further development will have improved biological properties relative to the parent antibody from which they are generated. A convenient way for generating such substitutional variants is affinity maturation using phage display.
  • hypervariable region sites e.g. 6-7 sites
  • the antibody variants thus generated are displayed in a monovalent fashion from filamentous phage particles as fusions to the gene III product of M 13 packaged within each particle.
  • the phage-displayed variants are then screened for their biological activity (e.g. binding affinity) as herein disclosed.
  • alanine scanning mutagenesis can be performed to identify hypervariable region residues contributing significantly to antigen binding.
  • Such contact residues and neighboring residues are candidates for substitution according to the techniques elaborated herein. Once such variants are generated, the panel of variants is subjected to screening as described herein and antibodies with superior properties in one or more relevant assays may be selected for further development.
  • Another type of amino acid variant of the antibody alters the original glycosylation pattern of the antibody. Such altering includes deleting one or more carbohydrate moieties found in the antibody, and/or adding one or more glycosylation sites that are not present in the antibody.
  • N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue.
  • the tripeptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain.
  • O-linked glycosylation refers to the attachment of one of the sugars N- aceylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used.
  • glycosylation sites to the antibody is conveniently accomplished by altering the amino acid sequence such that it contains one or more of the above-described tripeptide sequences (for N-linked glycosylation sites).
  • the alteration may also be made by the addition of, or substitution by, one or more serine or threonine residues to the sequence of the original antibody (for O-linked glycosylation sites).
  • the carbohydrate attached thereto may be altered.
  • antibodies with a mature carbohydrate structure that lacks fucose attached to an Fc region of the antibody are described in US Pat Appl No US 2003/0157108 (Presta, L.). See also US 2004/0093621 (Kyowa Hakko Kogyo Co., Ltd).
  • Antibodies with a bisecting N-acetylglucosamine (GIcNAc) in the carbohydrate attached to an Fc region of the antibody are referenced in WO 2003/011878, Jean-Mairet et al. and US Patent No. 6,602,684, Umana et al.
  • Antibodies with at least one galactose residue in the oligosaccharide attached to an Fc region of the antibody are reported in WO 1997/30087, Patel et al. See, also, WO 1998/58964 (Raju, S.) and WO 1999/22764 (Raju, S.) concerning antibodies with altered carbohydrate attached to the Fc region thereof. See also US 2005/0123546 (Umana et al.) on antigen-binding molecules with modified glycosylation.
  • the preferred glycosylation variant herein comprises an Fc region, wherein a carbohydrate structure attached to the Fc region lacks fucose. Such variants have improved ADCC function.
  • the Fc region further comprises one or more amino acid substitutions therein which further improve ADCC, for example, substitutions at positions 298, 333, and/or 334 of the Fc region (Eu numbering of residues).
  • Examples of publications related to "defucosylated” or "fucose-def ⁇ cient" antibodies include: US 2003/0157108; WO 2000/61739; WO 2001/29246; US 2003/0115614; US 2002/0164328; US 2004/0093621; US 2004/0132140; US 2004/0110704; US 2004/0110282; US 2004/0109865; WO 2003/085119; WO 2003/084570; WO 2005/035586; WO 2005/035778; WO2005/053742; Okazaki et al.
  • Examples of cell lines producing defucosylated antibodies include Lee 13 CHO cells deficient in protein fucosylation (Ripka et al. Arch. Biochem. Biophys. 249:533-545 (1986); US Pat Appl No US 2003/0157108 Al, Presta, L; and WO 2004/056312 Al, Adams et al., especially at Example 11), and knockout cell lines, such as alpha-1,6- fucosyltransferase gene, FUT8, knockout CHO cells (Yamane-Ohnuki et al. Biotech. Bioeng. 87: 614 (2004)).
  • Nucleic acid molecules encoding amino acid sequence variants of the antibody are prepared by a variety of methods known in the art. These methods include, but are not limited to, isolation from a natural source (in the case of naturally occurring amino acid sequence variants) or preparation by oligonucleo tide-mediated (or site-directed) mutagenesis, PCR mutagenesis, and cassette mutagenesis of an earlier prepared variant or a non-variant version of the antibody.
  • the antibody of the invention may be desirable to modify the antibody of the invention with respect to effector function, e.g. so as to enhance ADCC and/or CDC of the antibody.
  • This may be achieved by introducing one or more amino acid substitutions in an Fc region of an antibody.
  • cysteine residue(s) may be introduced in the Fc region, thereby allowing interchain disulfide bond formation in this region.
  • the homodimeric antibody thus generated may have improved internalization capability and/or increased complement-mediated cell killing and ADCC. See Caron et al., J. Exp Med. 176:1191-1195 (1992) and Shopes, J. Immunol. 148:2918-2922 (1992).
  • Homodimeric antibodies may also be prepared using heterobifunctional cross-linkers as described in Wolff et al. Cancer Research 53:2560-2565 (1993).
  • an antibody can be engineered that has dual Fc regions and may thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al Anti-Cancer Drug Design 3:219-230 (1989).
  • WO 00/42072 (Presta, L.) describes antibodies with improved ADCC function in the presence of human effector cells, where the antibodies comprise amino acid substitutions in the Fc region thereof.
  • the antibody with improved ADCC comprises substitutions at positions 298, 333, and/or 334 of the Fc region.
  • the altered Fc region is a human IgGl Fc region comprising or consisting of substitutions at one, two or three of these positions.
  • Antibodies with altered CIq binding and/or CDC are described in WO 99/51642, US Patent No. 6,194,551Bl, US Patent No. 6,242,195Bl, US Patent No. 6,528,624Bl and US Patent No. 6,538,124 (Idusogie et al).
  • the antibodies comprise an amino acid substitution at one or more of amino acid positions 270, 322, 326, 327, 329, 313, 333 and/or 334 of the Fc region thereof.
  • a salvage receptor binding epitope refers to an epitope of the Fc region of an IgG molecule ⁇ e.g., IgGi, IgG 2 , IgG 3 , or IgG 4 ) that is responsible for increasing the in vivo serum half-life of the IgG molecule.
  • IgGi IgGi, IgG 2 , IgG 3 , or IgG 4
  • Antibodies with substitutions in an Fc region thereof and increased serum half- lives are also described in WO00/42072 (Presta, L.).
  • anti-CD20 antibody formulations are described in WO98/56418, expressly incorporated herein by reference.
  • Another formulation is a liquid multidose formulation comprising the anti-CD20 antibody at 40 mg/mL, 25 mM acetate, 150 mM trehalose, 0.9% benzyl alcohol, 0.02% polysorbate 20 at pH 5.0 that has a minimum shelf life of two years storage at 2-8 0 C.
  • Another anti-CD20 formulation of interest comprises lOmg/mL antibody in 9.0 mg/mL sodium chloride, 7.35 mg/mL sodium citrate dihydrate, 0.7mg/mL polysorbate 80, and Sterile Water for Injection, pH 6.5.
  • Yet another aqueous pharmaceutical formulation comprises 10-30 mM sodium acetate from about pH 4.8 to about pH 5.5, preferably at pH5.5, polysorbate as a surfactant in a an amount of about 0.01-0.1% v/v, trehalose at an amount of about 2-10% w/v, and benzyl alcohol as a preservative (U.S. 6,171,586).
  • Lyophilized formulations adapted for subcutaneous administration are described in WO97/04801. Such lyophilized formulations may be reconstituted with a suitable diluent to a high protein concentration and the reconstituted formulation may be administered subcutaneously to the mammal to be treated herein.
  • One formulation for the humanized 2H7 variants is antibody at 12-14 mg/mL in
  • 2H7 variants and in particular Variant A is formulated at 20mg/mL antibody in 1OmM histidine sulfate, 60mg/ml sucrose., 0.2 mg/ml polysorbate 20, and Sterile Water for Injection, at pH5.8.
  • the formulation herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other.
  • the effective amount of such other agents depends on the amount of antibody present in the formulation, the type of disease or disorder or treatment, and other factors discussed above. These are generally used in the same dosages and with administration routes as described herein or about from 1 to 99% of the heretofore employed dosages.
  • the formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes. V. Articles of manufacture
  • articles of manufacture containing materials useful for the treatment of autoimmune diseases are provided.
  • the invention provides an article of manufacture comprising: (a) a container comprising an antagonist such as an antibody that binds to a B-cell surface marker (e.g., a CD20 antibody) (preferably the container comprises the antibody and a pharmaceutically acceptable carrier or diluent within the container); and (b) a package insert with instructions for treating an autoimmune disease, such as rheumatoid arthritis in a subject, wherein the instructions indicate that the subject is administered the complete therapeutically effective amount of the antagonist or antibody (e.g., CD20 antibody) as single intravenous infusion.
  • an antagonist such as an antibody that binds to a B-cell surface marker (e.g., a CD20 antibody)
  • the container comprises the antibody and a pharmaceutically acceptable carrier or diluent within the container
  • a package insert with instructions for treating an autoimmune disease such as rheumatoid arthritis in a subject, wherein the instructions indicate that
  • the article of manufacture herein further comprises a container comprising a second medicament, wherein the antagonist or antibody is a first medicament, and which article further comprises instructions on the package insert for treating the subject with the second medicament, in an effective amount.
  • the second medicament may be any of those set forth above, with an exemplary second medicament being those set forth above, including an antibiotic, an immunosuppressive agent, a disease-modifying anti-rheumatic drug (DMARD), a pain-control agent, an integrin antagonist, a non-steroidal anti-inflammatory drug (NSAID), a cytokine antagonist, bisphosphonate, or a hormone, or a combination thereof, more preferably a DMARD, NSAID, pain-control agent, or immunosuppressive agent.
  • the second medicament is methotrexate.
  • the package insert is on or associated with the container.
  • Suitable containers include, for example, bottles, vials, syringes, etc.
  • the containers may be formed from a variety of materials such as glass or plastic.
  • the container holds or contains a composition that is effective for treating the target autoimmune disease and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
  • At least one active agent in the composition is the CD20 antagonist, such as a CD20 antibody.
  • the article of manufacture may further comprise an additional container comprising a pharmaceutically acceptable diluent buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution, and/or dextrose solution.
  • a pharmaceutically acceptable diluent buffer such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution, and/or dextrose solution.
  • BWFI bacteriostatic water for injection
  • phosphate-buffered saline such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution, and/or dextrose solution.
  • BWFI bacteriostatic water for injection
  • phosphate-buffered saline such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution, and/or dextrose solution.
  • the humanized 2H7 antibody variants were prepared and assayed for biological function including human CD20 binding affinity, effector functions and B cell depletion were as described in WO 04/056312, incorporated herein by reference in its entirety.
  • the murine 2H7 antibody variable region sequences and the chimeric 2H7 with the mouse V and human C have been described, see, e.g., U.S. patents 5,846,818 and 6,204,023, incorporated herein by reference in their entirety.
  • OCR ocrelizumab
  • RA moderate to severe rheumatoid arthritis
  • MTX concomitant methotrexate
  • a randomized placebo-controlled, multicenter, Phase I/II study of the safety of escalating single intravenous doses of rhuMAb 2H7 was conducted in patients with moderate to severe rheumatoid arthritis receiving stable doses of concomitant methotrexate but with unsatisfactory clinical response.
  • the objective of the trial was to evaluate the safety and tolerability in combination with methotrexate (MTX) in patients with moderate to severe rheumatoid arthritis (RA) of escalating single intravenous (IV) doses of rhuMAb 2H7.
  • MTX methotrexate
  • RA moderate to severe rheumatoid arthritis
  • IV escalating single intravenous
  • Part I - Dose Escalation Patients receive a single IV infusion of rhuMAb 2H7 or placebo equivalent at one of the following dose levels: Group 1 : 400 mg Group 2: 1000 mg Group 3: 1500 mg Dose escalation occurs after the treatment of a minimum of 10 patients per dose level (8 active; 2 placebo). The decision to escalate is based on a review of the data from the previous group within the study. The number of dose-limiting toxicities will be assessed and depending on this number, the study may proceed to the next dose level or additional patients may be enrolled at the same dose level.
  • C-reactive protein > 1.5 mg/dL or erythrocyte sedimentation rate > 28 mm/hr at screening
  • Corticosteroid dose not to exceed 10 mg/day prednisone or equivalent, stable for the last 4 weeks prior to screening
  • Prophylaxis (recommended) - Prophylactic does of acetaminophen and diphenhydramine (or other non-sedating antihistamine), give 30-60 minutes before the infustion of rhuMAB 2H7 is initiated, are recommended.
  • Methotrexate (required) - At a stable weekly dose of 10-25 mg (oral or parenteral); provided by the study center's pharmacy
  • Corticosteroids (optinal) - Continue at stable oral doses of up to 10 mg/day prednisone or prednisone equivalent
  • rhuMAb 2H7 will be at a concentration of 20 mg/mL.
  • rhuMAb 2H7 must be diluted in 0.9% sodium chloride before infusion, to provide the appropriate dose in a volume of 250 or 500 mL (dilution information is provided in Appendix 3 to the Protocol)
  • Serum immunoglobulin concentrations (IgG, IgM, IgA, IgE) Serum concentration of tetanus toxoid antibodies Peripheral B-cell counts; T-cell counts Efficacy - Percentage of patients with clinical responses of 20%, 50% and 70% according to ACR criteria and the components of this outcome measure at Week 24, using Day 1 pre-infusion ACR core set values as baseline.
  • AIl analyses will be exploratory in nature. Patients will be grouped according to treatment actually received. All patients who receive any study drug (rhuMAb 2H7 or placebo) will be included for purposes of analysis.
  • Control (placebo) patients at the different dose levels will be combined into one control group. All results will be presented separately for the control group and each of the active dose groups: 400 mg, 1000 mg, 1500 mg and 2000 mg. Two subgroup analyses will be conducted: one based on all enrolled patients, and the other based on those patients who are randomized in Part II of the study after completion of dose escalation in Part I.
  • Serum concentrations of rhuMAb 2H7 and computed pharmacokinetic parameters will be listed by patient and dose group and summarized descriptively (mean, standard deviation, percent coefficient of variation, minimum, maximum). Individual and mean concentration versus time plots will be presented on both linear and logarithmic scales.
  • Pharmacokinetic parameters will be computed using non-compartmental methods.
  • concentrations below the limit of quantification of the assay will be deleted or assigned a numeric value based on the lower reporting limit of the assay.
  • the B-cell depletion profile for each patient will be determined and summarized descriptively for each dose level.
  • the pharmacodynamics of peripheral B-cell depletion and repletion will be characterized by the extent and duration of depletion at each dose level.
  • a prospective analysis plan will be prepared for providing population pharmacokinetic modeling as a pharmacokinetic/ pharmacodynamic analysis of the relationship between the pharmacokinetics of rhuMAb 2H7 and peripheral B-cell depletion and repletion.
  • Formulation: rhuMAb 2H7 drug product is manufactured by Genentech, as a sterile, clear, colorless, preservative free liquid intended for dilution for IV administration.
  • the rhuMAb 2H7 drug product is supplied at a concentration of 20 mg/mL in 10 cc single- use vials, which contain a nominal 10 mL (200 mg) of rhuMAb 2H7 per vial.
  • the rhuMAb 2H7 drug product is formulated in 10 mM histidine sulfate, 60 mg/mL sucrose, 0.2 mg/mL polysorbate 20, and Sterile Water for Injection. The pH is adjusted to 5.8. rhuMAb 2H7 drug product must be diluted before administration.
  • Solutions of rhuMAb 2H7 for IV administration are prepared by dilution of the drug product into an infusion bag containing 0.9% sodium chloride, to a final drug concentration of 1.6-6 mg/mL.
  • rhuMAb 2H7-matching placebo is also supplied in 10 cc single-use vials that contain a nominal 10 mL of placebo solution per vial. It is identical in composition to the rhuMAb 2H7 drug product but does not contain rhuMAb 2H7.
  • rhuMAb 2H7 placebo solutions for IV administration are prepared by dilution of the rhuMAb 2H7 placebo into infusion bags containing 0.9% sodium chloride, using an identical procedure as for the rhuMAb 2H7 drug product.
  • Study drug should be given as a slow IV infusion at the rates shown. The rates are dependent on the dose to be administered and will not exceed 250 mL/hr. It should not be administered as an IV push or bolus. Study drug infusions should be made through a dedicated line. Isotonic 0.9% sodium chloride solution should be used as an infusion vehicle. It is recommended that patients receive prophylactic treatment with acetaminophen (1 g) and diphenhydramine HCl (50 mg; or equivalent dose of similar agent) by mouth 30-60 minutes prior to the start of an infusion. All doses except 2000 mg will be administered in a volume of 250 mL; the 2000 mg dose (and matching placebo) will be administered in a volume of 500 mL.
  • the rhuMAb 2H7 drug product is supplied as a liquid at a concentration of 20 mg/mL in 10 cc single-use vials, which contain a nominal 10 mL (200 mg) of rhuMAb 2H7 per vial.
  • Matching placebo, identical in composition but not containing rhuMAb 2H7 is also supplied as a liquid in 10 cc single use vials, which contain a nominal 10 mL of placebo solution per vial.
  • the rituximab (MabThera) prescribing information provides the following information on infusion:
  • the recommended initial rate for infusion is 50 mg/hr; after the first 30 minutes, it can be escalated in 50 mg/hr increments every 30 minutes to a maximum of 400 mg/hr. If hypersensitivity or an infusion related event develops, the infusion should be temporarily slowed or interrupted and can continue at one half the previous rate upon improvement of symptoms. If the same adverse reactions occur severely for a second time the decision to stop treatment should be considered. The infusion rate may be increased upon improvement of symptoms.
  • Subsequent Infusions Infuse at initial rate of 100 mg/hr and increase by 100 mg/hr increments at 30 minute intervals, to a maximum of 400 mg/hr.
  • Results 70% and 89% of the OCR and PLO groups were female and, at baseline, the mean numbers of tender and swollen joints were 16 & 17 and 28 & 28, ESR 45 & 49, CRP 25 & 21, RF+ 92% & 94% respectively.
  • B cell depletion (96% for OCR at week 12) and clinical responses were observed in all OCR dose groups
  • ACR20/50/70 responses at week 24 were 57%, 31% and 15% for the combined OCR group and 40%, 10% and 3% for PLO group respectively.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne l'utilisation d'un antagoniste de CD20 dans la fabrication d'un médicament pour le traitement d'une maladie auto-immune, le médicament étant destiné à être administré à un patient humain par perfusion intraveineuse (IV) unique thérapeutiquement efficace dudit antagoniste. L'antagoniste de CD20 est de préférence un anticorps anti-CD20, et la maladie auto-immune est de préférence la polyarthrite rhumatoïde.
EP08804245A 2007-09-24 2008-09-16 Dose fixe d'injection unique d'ocrelizumab (2h7) Withdrawn EP2197916A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97464107P 2007-09-24 2007-09-24
GBGB0718684.4A GB0718684D0 (en) 2007-09-24 2007-09-24 Treatment method
PCT/EP2008/062286 WO2009040268A1 (fr) 2007-09-24 2008-09-16 Dose fixe d'injection unique d'ocrelizumab (2h7)

Publications (1)

Publication Number Publication Date
EP2197916A1 true EP2197916A1 (fr) 2010-06-23

Family

ID=38670460

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08804245A Withdrawn EP2197916A1 (fr) 2007-09-24 2008-09-16 Dose fixe d'injection unique d'ocrelizumab (2h7)

Country Status (10)

Country Link
EP (1) EP2197916A1 (fr)
JP (1) JP2011501734A (fr)
CN (1) CN101809036A (fr)
AR (1) AR068531A1 (fr)
CA (1) CA2700351A1 (fr)
CL (1) CL2008002817A1 (fr)
GB (1) GB0718684D0 (fr)
PE (1) PE20091078A1 (fr)
TW (1) TW200918091A (fr)
WO (1) WO2009040268A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2380911T1 (en) 2003-11-05 2018-07-31 Roche Glycart Ag ANTIGEN-RELATED PATIENTS WITH INCREASED ATTENTION ON THE RECEPTOR FC AND EFFECTORAL FUNCTION
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
KR20180075537A (ko) * 2015-10-06 2018-07-04 제넨테크, 인크. 다발성 경화증을 치료하기 위한 방법
IL261515B2 (en) * 2016-03-07 2024-04-01 Sanofi Biotechnology Preparations and methods for the treatment of rheumatoid arthritis
KR20200035441A (ko) * 2017-08-08 2020-04-03 에프. 호프만-라 로슈 아게 Dlbcl 환자 하위그룹의 오비누투주맙 치료
AU2019347730A1 (en) * 2018-09-24 2021-03-25 Janssen Biotech, Inc. Method of providing safe administration of an anti-CD154 antibody

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006076651A2 (fr) * 2005-01-13 2006-07-20 Genentech, Inc. Procede de traitement

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0316779B1 (pt) * 2002-12-16 2020-04-28 Genentech Inc anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados
US20080213273A1 (en) * 2005-07-25 2008-09-04 Trubion Pharmaceuticals Inc. Single dose use of CD20-specific binding molecules
MY149159A (en) * 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006076651A2 (fr) * 2005-01-13 2006-07-20 Genentech, Inc. Procede de traitement

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2009040268A1 *

Also Published As

Publication number Publication date
PE20091078A1 (es) 2009-07-23
JP2011501734A (ja) 2011-01-13
AR068531A1 (es) 2009-11-18
WO2009040268A1 (fr) 2009-04-02
GB0718684D0 (en) 2007-10-31
CN101809036A (zh) 2010-08-18
CA2700351A1 (fr) 2009-04-02
TW200918091A (en) 2009-05-01
CL2008002817A1 (es) 2009-10-16

Similar Documents

Publication Publication Date Title
US10654940B2 (en) Method for treating joint damage
US20060246004A1 (en) Antibody variants and uses thereof
US20080095771A1 (en) Treatment Method
AU2009313756B2 (en) Method and formulation for reducing aggregation of a macromolecule under physiological conditions
AU2005249393A1 (en) Preventing autoimmune disease by using an anti-CD20 antibody
US20100021460A1 (en) Methods of Treating Autoimmune Diseases Using CD4 Antibodies
EP2197916A1 (fr) Dose fixe d'injection unique d'ocrelizumab (2h7)
US20090214561A1 (en) Treatment method
AU2012227327A1 (en) Method for treating joint damage

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100426

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20131015

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140226